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ABSTRACT
Ubiquitin chains of specific linkages are assembled by ubiquitin conjugating enzymes
(E2s) and ubiquitin ligases (E3s) to encode unique signals in the cell. Nevertheless, ubiquitin
chains are often trimmed by deubiquitinases to reverse encoded signals. Given that there are
altogether eight linkage types of polyubiquitin chains, how E2s, E3s and DUBs mediate ubiquitin
chains in a linkage-specific manner is still an open question. In this thesis, an interdisciplinary
approach including organic synthesis, genetic code expansion, protein engineering has been
investigated to stress this intriguing question. To this end, linkage-specific diUB featuring a thiol
group embedded near the isopeptide bond site was prepared in large scale and it was readily used
for activity-based protein profiling to uncover more linkage-specific ubiquitin chain regulators by

converting it into a probe with an electrophilic trap, or for structure determination by conjugating
it to corresponding chain-specific E2 or E3s. Taken together, these linkage-specific diUB probes
should provide access for structural biologists to map dynamic, transient, weak protein-protein
interactions in UB transfer, therefore to uncover detailed mechanism underlying chain specificities
of E2, HECT E3 or DUB with direct evidences and to reconstitute full pictures of E2, E3 mediated
ubiquitination on substrates and linkage-specific chain elongation.
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1

INTRODUCTION

As a fundamental mechanism to modulate protein function in the cell, post-translational
modification (PTM) regulates most if not all biological processes1, 2. The side chain of lysine with
a primary amino group often serves a reactive handle for several important PTMs including
methylation, acetylation and ubiquitination1, 2. Among them, ubiquitination is particularly
intriguing in regards of structures and functions; unlike other PTMs such as phosphorylation,
methylation, acetylation, in which the modifying groups are relatively simple and small,
ubiquitination involves attachment of one or even more entire proteins, namely ubiquitin,
covalently to a desired substrate, rendering it very challenging yet interesting to study.
Ubiquitin was first known to post-translationally target eukaryotic proteins for degradation
in the late 1970s.3-6 This discovery was recognized by the awarding of the 2004 Nobel Prize in
Chemistry to Aaron Ciechanover, Avram Hershko, and Irwin Rose. Until the mid-90’s, this PTM
was believed to conduct primarily proteasomal signals; however, a large portion of nonproteasomal functions in, for example, endocytosis and lysosomal targeting, subcellular
localization of proteins, autophagy, DNA repair, and kinase activation has been reported.
Nevertheless, malfunction of the UB system plays causal roles in diseases such as cancer,
inflammatory diseases, and neurodevelopmental and degenerative disorders.7-11

1.1

Ubiquitin and E1-E2-E3 cascade
Ubiquitin (UB), the 76-residue protein riding on a E1-E2-E3 enzymatic cascade, is a key

note in the tunes of cell signaling of ubiquitination. In this process, the C-terminus of ubiquitin is
covalently attached to a ε-amine of a lysine forming an isopeptide bond. (Figure 1-1).
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Figure 1-1 Isopeptide formation in substrate ubiquitination

In nature, amide bond forming is usually hard and requires additional activation of the
carboxyl beforehand. Fortunately, a ubiquitin pathway involving three different sets of enzymes,
known as E1-E2-E3 cascade, elegantly facilitates the conjugation between ubiquitin and the
desired substrate. (Figure 1-2) 12-16 In this cascade, ubiquitin and ATP will firstly bind to a 110 kD
enzyme, namely ubiquitin activating enzyme (E1), in an adjacent manner so that a condensation
reaction will happen yielding UB-AMP and pyrophosphate. In this first half reaction E1 catalyzed,
the C-terminus of ubiquitin is activated through an energy consuming process and the newlyformed AMP ester is prone to nucleophilic attack by a catalytic cysteine on E1 forming a thiol
ester bond often known as UB~E1 where as “~” designates a thioester bond. On the second half
of the reaction, E1 will transfer this charged ubiquitin onto ubiquitin conjugating enzyme (E2)
which is bound to E1. Upon Ub~E2, a third component of enzymes, ubiquitin ligases or E3s with
their unique substrate binding domain will recruit corresponding E2s charged with ubiquitin and
carry out the transfer to a specific lysine of the target protein to achieve ubiquitination with an
isopeptide bond.
Ubiquitin ligases (E3) play a very crucial role in precisely delivering ubiquitin to predefined targets and fall into different classes based upon their working modes to engage the UB~E2
conjugate. HECT-type E3s with the name coming from Homologous to the E6-AP Carboxyl
Terminus bear a similar catalytic cysteine like E2s that can form Ub~E3 thus indirectly
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ubiquitinate substrates, whereas RING-type E3s (Really-Interesting-New-Genes) often serve as a
platform and recruit corresponding E2s loaded with UB and substrate at the same time to facilitate
a direct transfer.

Figure 1-2 E1-E2-E3 cascade in ubiquitination pathway

E1-E2-E3 cascade enables regulations from different steps of ubiquitin transfer and ensures
the accuracy of modifications on desired substrates. There are 2 E1s, 40 E2s, and more than 600
E3s encoded in the human genome that assemble a complex network of UB transfer. More detailed
E1, E2, HECT or RING type E3 structures and functions are discussed in later chapters. (Chapter
5.1, Chapter 1.3 and Chapter 4.3).

1.2

Ubiquitin chains: topologies and functions
Within E1-E2-E3 cascade for ubiquitin transfer, the assignment of each E1, E2, E3 to

facilitate ubiquitination of a target substrate at a desired position of a lysine residue is very
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complicated, resulting in the complexity of ubiquitination from one dimension.17 Nevertheless,
aiming at one particular substrate, single UB can be attached to one specific position of lysine
residue (mono-ubiquitination) or several different positions (multiple-ubiquitination); several UBs
can modify the same lysine residue in a manner of forming homotypic or heterotypic UB chains
(poly-ubiquitination).18-20 In addition to these, UB on the substrates can also be post-translationally
modified with acetylation21 or phosphorylation22-24. Adding together, ubiquitination patterns
provides another dimension of complexity in ubiquitination, also known as ubiquitin code19, 20.
Deciphering the ubiquitin code is extremely difficult yet very interesting due to the complexity of
ubiquitin code and availability of homogeneous ubiquitin chains.

1.2.1 Ubiquitin chains with different linkage types and their structural features
Based upon the sequence and structure of ubiquitin (Figure 3), there are altogether seven
lysine, namely K6, K11, K27, K29, K33, K48, K63 and one methionine at N-terminus (M1) that
can potentially serve as ubiquitin chain acceptors. Previous proteomics studies suggested that all
possible linkage types co-exist in cells with very different abundances (K48 51.7%, K63 37.8%,
K29 7.8%, K11 2.2%, K6 0.5% M1 ＜ 0.5%, K27 ＜ 0.5% K33 ＜ 0.5% respectively).

25-29

Consequently, M1, K6, K11, K27, K29 and K33 linkages are usually referred as “atypical”
ubiquitin chain types.
The variety of cellular processes initiated and regulated by ubiquitination has been
indicated in part by the structural diversity of different ubiquitin linkage types. Although the
ubiquitin chains are overall dynamic, structural analysis including X-ray crystallography and
nuclear magnetic resonance (NMR) spectroscopy, has revealed topologies of ubiquitin dimers. 3036

(Figure 1-4) The conformations of ubiquitin dimers fall into two categories: K6, K11, K29, K33

5

and K48 type chains tend to form a “closed” topology with intact intramolecular interfaces while
K63 and M1 type chains adopt “open” architectures without much interaction region except for
the linkage point.37 However, the structure of di-Ubiquitin with K27 linage has not been resolved
yet.

Figure 1-3 Ubiquitin chain formation
(A) Ubiquitin protein sequence, lysines that can be conjugated with another molecule of ubiquitin are
bolded and a conserved diGly motif at C-terminus of UB is colored in red. (B) Structure of ubiquitin
highlighting the eight sites of ubiquitination18. (C) Isopeptide formation between donor and acceptor
UBs.

Ubiquitin features several surface patches, for example, hydrophobic regions around I36
and I44, that are crucial elements recognized by ubiquitin chain regulators. These patches are
positioned uniquely due to the topologies of linkage-specific polyubiquitin chains with distinct
projection patterns of hydrophobic areas (Figure 1-4), which serve as structural bases for signal
specificity of various cellular event summarized in the next section.
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Figure 1-4 Ubiquitin chain topologies
PDB number: K6 2XK5, K11 1AAR, K29 4S22, K33 2XK5, K48 3N0B, K63 2JF5, M1 2W9N
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1.2.2 Biological significances of linkage-specific ubiquitin chains
Ubiquitination study had been limited to K48-and K63-linked polymers for many years
until the late 2000s when innovative technologies in molecular biology and mass spectrometry
reveal the biological significances of “atypical” ubiquitin chains.18, 19 (Figure 1-5)

Figure 1-5 Physiological roles associated with individual chain types.
A small selection of E2 or E3 enzymes that assemble and DUBs that disassemble ubiquitin chains
with linkage preferences is indicated. Below, cartoons illustrate some of the biological processes
that particular linkage types have been linked with as discussed in the section.

1.2.2.1 M1 linkages
The role of linear ubiquitin chains (M1) is heavily implicated in regulation of innate
immune signaling associate with NF-κB nuclear translocation and activation. (Figure 1-6) Upon
cytokine receptors and toll-like receptors (TLRs) activation, downstream kinases and E3 ligases
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are further activated to phosphorylate or ubiquitinate κB kinase (IKK) complex comprised of
NEMO, IKKα and IKKβ subunits; activated IKK complex will phosphorylate and then cause
degradation of NF-κB inhibitor, or IκB with ubiquitination by an E3 ligase SCF(β-TrCP),
resulting in the release and translocation of NF-κB to induce transcription for inflammatory and
immune response. 38, 39 In the process, ubiquitination of IKK complex by TRAF6 forming K63type poly-ubiquitin chains on IKKα and IKKβ and more importantly ubiquitination by LUBAC,
a multi-subunit RBR or Ring-Between-Ring E3 ligase40 comprising HOIP, HOIL-1L and
SHARPIN, forming M1-type poly-ubiquitin chains on NEMO are critical for IKK complex full
activation41, 42 in a way that M1-linked chains will bind to a linear-chain specific ubiquitin
binding domain (UBD) on NEMO to recruit TAK1 and then to further activate IKKα and IKKβ.43

Figure 1-6 M1 and K63 ubiquitin chains in NF-κB activation18
K63-polyubiquitination by TRAF6 and M1-polyubiquitination by LUBAC (HOIP) are crucial components
for kinase inhibitory kinases TAK, IKK activation to release and translocate NF- κB.
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1.2.2.2 K11 linkages
So far K11-linked ubiquitin chains are mainly associated with cell cycle regulation. During
mitosis, the abundance of K11 linkages increases dramatically when metazoan anaphasepromoting complex, or APC/C is active.35

It was believed that APC/C initiates substrate

ubiquitination and chain formation together with an E2 enzyme UBE2C where mainly K48 or K63
chains are assembled.44 Subsequently, another E2 enzyme UBE2S further elongates the UB chains
of K11 linkage.45 The ubiquitinated substrates by UBE2C, UBE2S and APC/C are targeted for
proteasomal degradation, which results in mitotic exit. A detailed mechanism in the event revealed
by recent structural studies is discussed in later chapter. (Chapter 4.1 and Chapter 4.3)
1.2.2.3 K48 linkages
The K48 linkages of ubiquitin chains are the most abundant one as previously described.
And the major role is targeting proteins for proteasomal degradation.20 Traditionally, tetraubiquitination of K48 linkage is regarded as a minimum requirement to be efficiently targeted to
26S proteasome.46 However, the dogma was challenged by recent studies showing that multipleubiquitination with various short chains can promote proteasomal degradation.

47

Nevertheless,

some non-degradative purposes of K48 linkages are reported where protective UBDs seem to play
a role. 48, 49
1.2.2.4 K63 linkages
As discussed in M1 linkages section, the K63 type ubiquitin chains are found significantly
in immune response of NF-κB pathways where TRAF family E3 ligases catalyze K63polyubiquitination for “upstream” kinase TAK1 and “downstream” kinase IKK activation. (Figure
1-6) Notably, there are UBD on TAK1 for chains of K63- linkage, called TAB2 and TAB3.50, 51
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Along with similar K11 poly-ubiquitin chain recognizing UBD on NEMO (UBAN domain), these
features serve as structural basis for ubiquitin chain formation and NF- κB activation.52
The role of K63 chains is also heavily implicated for DNA double-strand break (DSB)
repair. DSBs are detected by the Mre11-Rad50-Nbs1 (MRN) complex, which recruits and
activates the protein kinase ATM at the site of DNA damage (Figure 1-7) 53.ATM phosphorylate
H2AX and MDC1; phosphorylated MDC1 is recognized by the FHA domain of RNF8, a RING
domain E3 that functions together with Ubc13 to catalyze K63 polyubiquitination of target proteins
including H2AX and H2A. The K63 polyubiquitin chains bind to the RAP80 UIM domain, thereby
recruiting the BRCA1 complex that includes Abraxas, BARD1, and BRCC36.54

Figure 1-7 Role of K63 polyubiquitination in DNA damage repair54

1.2.2.5 K6, K27, K29, K33 chains
The significances of other “atypical” ubiquitin chains are uncovered gradually by recent
studies with still a lot more to learn. DNA repair associated heterodimeric E3 ligase BRCA1BARD1 aforementioned has been reported to assembly K6 poly-ubiquitin chains with no protein
stability implication.55, 56 Another evidence of K6 poly-ubiquitination was found in mitochondrial
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outer membrane (MOM) proteins upon depolarization of the organelle, most likely assembled by
Parkin E3 ligase. 57
K27 chains are reported58 to be formed on histone H2A proteins in the process of DNA
damage response; crucial mediators in this event, including 53BP1, Rap80, RNF168 and RNF169
were known to recognize K27 polyubiquitination H2A.
Recent studies show that Smad ubiquitination regulatory factor 1 (Smurf1) can modify
Axin with non-degradable K29-linked ubiquitin polymers. Axin is a scaffold protein in Wnt/βcatenin signaling pathway; Axin bearing K29 ubiquitin chains perturbs the ligand bindings for Wnt
co-receptors thus inhibits this process.59
K33- ubiquitin chains are associated with negative regulation of both T-cell antigen
receptor (TCR) 60 and AMP-activated protein kinase (AMPK)-related protein kinases61. Another
paper suggested K33 linkages are important for post-Golgi protein trafficking.62
Taken together, polyubiquitin chains mediate various signal pathways and cellular events
beyond proteasomal degradation. New functions of canonical ubiquitin chains are still under heavy
investigation, while the roles of atypical chains remain largely unclear.

1.3

Factors that associate with ubiquitin chains
The dynamic features of almost all post-translational modifications facilitate sophisticated

yet flexible regulations of biological processes to maintain steady states for all cells.1, 2 In the case
of ubiquitination, while distinct architectures of polyubiquitin chains are the structural basis of
various cellular functions, recognition and regulations of the lengths and linkage types of ubiquitin
chains are critical when building-up, removing and deciphering ubiquitin codes so that the
ubiquitination signals can be precise and reversible. The nature of these chains is determined
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largely by specific E2s and E3s involved, which together with E1, “write” the UB signal on
proteins.

Ubiquitination

is

a

reversible

process,

deubiquitinating

enzymes

(DUBs;

deubiquitinases), can either completely reverse or alternatively “edit” substrate-bound chains by
cleaving linkages with various degrees of specificity. The outcome of protein ubiquitination is
largely a function of the UB chain linkage in the context of the substrate and its recognition by the
many proteins containing UB-binding domains (UBD), which translate or “read” the UB code on
a particular protein.

1.3.1 E2 and E3 as ubiquitin code “writers”
The E1-E2-E3 cascade (Figure 1-2) “writes” the ubiquitin code by building up various
ubiquitin polymers on substrates. In this process, E2 and E3 are important players to determine
chain linkage types as E1 mainly focuses on activating ubiquitin and transferring loaded ubiquitin
to E2.
1.3.1.1 Ubiquitin conjugating enzymes (E2s)
E2s are at the crossroads regarding the linkage specificity of ubiquitination. Members of
this ~ 40-member family have a conserved UBC fold that is critical to interactions with both E1
and the various families of E3s.16, 63 This fold includes a catalytic Cys through which UB is bound
in a thioester linkage (E2~UB) after transesterification from E1. The N-terminal helix of UBC is
a key element for interacting with the UB-fold domain (UFD) of the E1 enzyme

64

. Besides the

UBC, various E2s may have extended N or C termini that affect their pairing with various E1 and
E3 enzymes.
E2s are the decision makers for ubiquitin chain initiation on a lysine of a substrate or
elongation on a lysine of an acceptor ubiquitin. Most of the time, different E2s are assigned for
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initiation or elongation. In the case of UBE2C, UBE2S and APC/C described in chapter 1.3.1.1,
UBE2C ubiquitinates APC/C substrates with short K48 ubiquitin chains before UBE2S further
elongates K11 chains specifically.
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A similar example is BRCA1-BARD1 ubiquitination

mentioned earlier where UBE2W or UBE2E2 initiates ubiquitination and heterodimeric UBE2NUBE2V1 or UBE2K specifically promote chain elongation66. Nevertheless, aforementioned
TRAF6 ubiquitination follows the same pattern with UBE2D to initiate and UBE2N–UBE2V1 to
elongate Lys63-linked ubiquitin chains during NF-κB activation.67 An exception in this case is
yeast E2 Cdc34, which initiates and elongates exclusive K48 polyubiquitin chains by itself when
associates with E3 SCF (Figure 1-8)68.

Figure 1-8 Cdc34 catalyzed ubiquitin chain initiation and elongation

Interestingly, E2s that initiate ubiquitination, especially UBE2D family members, lack the
selectivity of lysine residues on substrate. However, UBE2S elongates exclusive K11-linked
chains, UBE2N-UBE2V1 elongates K63 chains and UBE2K elongates K48 chain respectively.
While the molecular basis for K11 linkage specificity of UBE2S remains unclear, it has been
noticed that the efficient elongation of K48-specific the ubiquitin chain requires an interaction
between an acidic loop located near the active site in Cdc34 and the substrate loaded ubiquitin to
orient the attacking ε-amino group of Lys48.

69, 70

In addition, the crystal structure of yeast
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homologues UBE2N-UBE2V1, Ubc13-Mms2 bound with both donor and acceptor ubiquitin
provided direct evidence on the selectivity of lysine that can be conjugated with donor ubiquitin.
(Figure 1-9) 71 In Ubc13-Mms2, the donor ubiquitin is covalently linked to the catalytic Cysteine
in Ubc13, whereas the acceptor ubiquitin is noncovalently bound to the back of Mms2. The
interaction with Mms2 positions the acceptor ubiquitin relative to Ubc13 so that Lys63, but no
other Lys residue, can attack the thioester bond between the donor ubiquitin and Ubc13.

Figure 1-9 Crystal structure of Ubc13~donor Ub-Mms2 (PDB 2GMI)

1.3.1.2 HECT-type E3s
Another important “writer” of various ubiquitin chains is HECT E3s and RBR E3s with a
catalytic cysteine that can form a thioester bond with donor ubiquitin. In humans, this category
includes ~28 HECT E3s and 12 RING-Between-RING (RBR) E3s14, 72. Previous LC/MSMS data
suggested most HECT E3s have preference of linkage types during ubiquitination (Figure 1-10)
34

, somehow direct molecular evidence is still missing. Some recent studies addressing this

question are discussed in the later chapter. (Chapter 4.2)
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Figure 1-10 LC-MSMS data suggested specificity of polyubiquitin chain formed by HECT34

1.3.2 Deubiquitinating enzymes (DUBs) as ubiquitin code “erasers”
Ubiquitin chains are constantly trimmed or removed by DUBs, which account for more
than 100 genes in the human genome. 73, 74. A majority of DUBs are Cysteine proteases including
UB-specific proteases (USPs, 54 members in humans), ovarian tumor proteases (OTUs, 16
members), UB C-terminal hydrolases (UCHs, 4 members), Josephin DUBs, and as of late, the
motif interacting with ubiquitin (MIU)-containing novel DUB family (MINDYs, 4 members),
except for a sixth family that is Zn-dependent metalloproteases of the JAMM family (6 members).
75, 76

The catalytic domains of DUBs bear a shared primary recognition site, the S1 site, that can

bind with ubiquitin, which is the most important feature for DUB activity of editing ubiquitin
chains.77
However, how DUBs select which modifier to target, how DUBs approach their substrates
or ubiquitin chains are largely depend on other binding sites, such as S1’, S2, S2’. (Figure 1-11A
and B) These features result in different cognition and cleavage mechanism of DUBs, thereby
explain different preferences of DUB function. Some of DUB remove the endo ubiquitin or
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ubiquitin chains regardless of their length and linkages, regenerating unmodified substrates.
(Figure 1-11C) With few exception, USP superfamily of DUBs falls into this category by taking

off the substrate-bound proximal ubiquitin without much selectivity of ubiquitin linkage types. 78
Figure 1-11 Principles of DUB substrate recognition and linkage specificity
(A) Basic nomenclature for DUB ubiquitin-binding sites and a model diubiquitin substrate. (B) Defined S1 sites can
sufficient to recruitubiquitinated substrates while DUBs without S1’ site are non-specific (USP and UCH family
members). S1’ sites interacting with substrate proteins or proximal ubiquitin are the structural basis for substrate or
ubiquitin chain specificity. (OUT, JAMM, MINDY family members) (C) The binding features of DUB determine
the cleave sites and chain specificity. (D) Arrangement and nature of UB-binding sites in DUBs suggest the
cleavage modes: whether polyubiquitin is cleaved from the distal or the proximal end (exo-cleavage) or within a
chain (endo-cleavage).

A completely different types of DUBs recognize and cleave predefined ubiquitin chains
without much concern of the substrate (Figure 1-11D) whereas some DUBs of this category prefer
removal the distal ubiquitin one at a time, known as “exo”-cleavage while some DUBs, especially
members in OTUB superfamily, cleave the “endo” ubiquitin with a higher chain removal
efficiency75. Commonly, these DUBs feature an additional proximal ubiquitin binding site, S1’
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site, that can further orient the ubiquitin chain and facilitate the cleavage of an exposed C-terminus
of donor ubiquitin in a linkage-specific fashion.
The degree of linkage specificity varies between DUB families; MINDY DUBs are K48
specific whereby most JAMM metalloproteases cleave K63 chains exclusively. As describes
earlier, UCH and Josephin family members of DUB are promiscuous ubiquitin chain editors
without a defined S1’ site; therefore, they can barely cleave diubiquitin effectively.

79

Notably,

USPs without the same S1’ site are regarded as non-discriminable ubiquitin code “erasers” except
for CYCD (cylindromatosis-associateed DUB)80 and mitochondrial DUB USP30.81 CYCD is a
tumor-suppresser protein implicated in NF-κB pathway (Figure 1-6) where it selectively cleave
K63- and M1- polyubiquitin chains assembly by TRAF5 and LUBAC.82 Consequently, CYCD
deactivate NF-κB to negatively regulate NF-κB pathway and prevent tumor cell survival or
oncogenesis. A recent structural studies of CYCD bound of K63 or M1- di ubiquitin validates the
role of S1 and S1’ sites in ubiquitin chain recognition and specificity in ubiquitin chains. (Figure
1-12A)83
The most intriguing DUB class regarding their specificity towards various ubiquitin chains
is OTU family.84 OTUBLIN, an enzyme that equally crucial in NF-κB response, binds and cleaves
M1-linked ubiquitin chains exclusively.85 In addition, OTUB1 is one of the most abundant DUB
in cells with a remarkable specificity for K48 linked polyubiquitin chains86 whereas another
member of OTU family, Cezanne, is the only know DUB that target and cleave K11 chains with
high specificity87. Like CYCD, the crystal structures of DUBs in complex with their corresponding
di-ubiquitins revealed direct evidence of their chain specificity. (Figure 1-12B, C, D)
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Figure 1-12 Crystal structure of DUBs bound preferred di-Ub
(A) CYCD bound with K63- and M1- diUB respectively (PDB 3WXE, 3WXG)
(B) OTULIN bound with M1 diUB (PDB 2ZFY)
(C) OTUB1 bound with K48- diUB (PDB 4DDI)
(D) Cezanne bound with K11- diUB (PDB 1UBQ)

1.3.3 UB-binding domains (UBDs) as ubiquitin code “readers”
The various topologies of ubiquitin chains and ubiquitinated substrates provide the
molecular basis of ubiquitin codes that to be read so that unique modification will be interpreted
into specific outputs. This is accomplished usually through binding to over 20 specific Ubiquitinbinding domains, or UBDs. 88, 89 Depending on the recognition unit on UBDs, they mainly divide
into two superfamilies. The first group, including Ubiquitin-interacting motifs (UIM), Ubiquitinassociated domains (UBA) and Coupling ubiquitin to ER degradation domains (CUE), are made
from one to three α helixes. The linear polyubiquitin binding motif, UBAN, that described in
Chapter 1.2.2.1, also belongs to this group.43 Another superfamily of UBD utilizes zinc fingers
that recognition specific ubiquitin chains and these are comprised of NZF (novel zinc finger),
ZnF_UBP (UBP-type zinc finger), ZnF_A20 and UBZ. These readers of signals can recognize
various structural features on UB such as the classic hydrophobic patch surrounding Ile44, the
TEK box (Thr9-Glu10-Lys11), the loop region of Glu51-Lys63 and the C-terminal Gly of UB 89
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However, most UBDs bind to ubiquitin with low affinity, with the binding constants ranging from
several micromolar to several millimolar, which suggests that additional interactions or
components are important in the specificity recognition.53

1.4

Bioorganic and biochemical approaches to understand ubiquitin code
The complexity of ubiquitin codes provides sophisticated manipulation and tight regulation

of ubiquitin transfer within E1-E2-E3 cascade and specific ubiquitin chain formation, edition and
recognition, which in part explains the significance of ubiquitination as a ubiquitous posttranslational modification and errancy in ubiquitination pathway always results in serious
diseases.90-92 However, these different layers of complexity rise the difficulty in understand the
mechanisms in ubiquitination pathway and its regulation. Fortunately, to decipher the ubiquitin
code, previous biochemist and organic chemist had utilize various elegant approaches to
accomplish at least some part of this task.

1.4.1 Ubiquitin chain synthesis
1.4.1.1 Synthetic ubiquitin chains with solid-phase peptide synthesis
The availability of ubiquitin chains with predefined length and linkage types is
fundamental in understanding specific signals they convey. Unfortunately, utilizing linkagespecific E2s, such as E2-25K, which is known for building up K48-polyubiquitination, is not a
good choice in situ, simply because the length of ubiquitin chains cannot be manipulated without
extra mutations in donor ubiquitin to block further chain elongation.

93-95

Therefore, solid-phase

peptide synthesis (SPPS) has been widely used initially for this purpose. The general scheme for
ubiquitin chain synthesis via SPPS was shown in Scheme 1-1.
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Scheme 1-1 The general synthetic route for ubiquitin synthesis with solid-phase peptide
synthesis
Following this approach, total synthesis of diUB96, 97 and tetraUB98 of K48 linkage was
reported by Brik group and Ovaa group respectively, who are the pioneers for SPPS of ubiquitin
chains with predefined yet native linkages.99 Nevertheless, SPPS enables design and incorporation
of various reporting groups as warhead embedded in synthetic ubiquitin chains for labelling100
(with fluorophores of FRET pairs, for example) or probing101 applications. However, the pure
synthetic approach is believed to be tenuous and material-consuming requiring extra steps of
ligation and purification: the comfort length for SPPS is under 40 amino acids; synthesizing one
ubiquitin moiety usually requires one or two steps of native chemical ligation.
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1.4.1.2 Semi-synthetic ubiquitin chain with UAA incorporation.
More recently, Chin group and Fushman group

102, 103

separately reported to use a semi-

synthetic approach to generate linkage-specific ubiquitin dimers, which they name as “genetically
encoded orthogonal protection and activated ligation (GOPAL)”. GOPAL takes advantage of the
pyrrolysinyl-tRNA synthetase (PylRS) to incorporate a lysine analogue with protected -amino
group, namely BocK or CbzK to ensure the specificity of position to be modified; the remaining
amino functionalities (the N-terminal amine and six lysine residues) are globally protected with
orthogonal Cbz or Alloc groups. Acid treatment selectively removes the Boc group to unmask the
reactivity of the designated lysine, which is then used to couple with the intein-derived thioester
of donor UB that is also globally protected on the amines. After coupling, the protecting groups
are removed to afford diUB of a native linkage. Such an approach generates native isopeptide
linkages between the two recombinant UBs produced in E. coli. (Scheme 1-2)

Scheme 1-2 GOPAL approach for linkage-specific ubiquitin chain semi-synthesis

Another similar and even more elegant method for ubiquitin chains synthesis is
incorporating unnatural amino acid into acceptor ubiquitin for direct ligation to activated donor
ubiquitin without additional protection and deprotection on other amines.104 This method utilizing
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directed evolution for UAA incorporation, known as genetic code expansion (GCE) and will be
discussed in Chapter 2.2 extensively.
1.4.1.3 Engineered ubiquitin chains of nonnative linkages
Ubiquitin chains of nonnative linkages are a close mimic of native chains that can be
employed to reveal chain topology and identify reader proteins of ubiquitin chains; these linkages
are relatively easy to assemble with a wider choice of conjugating chemistry.
As previously mentioned, linkage-specific E2s provides a facile way to assemble tetra UB
chains or even longer conjugates with a periodic thioether linkage 105-107 (Scheme 1-3A). In such
a method, to control the length of ubiquitin chain, the very lysine on donor ubiquitin is mutated
into cysteine to block further elongation; the resulting diUB then reacts with ethyleneimine to

Scheme 1-3 Nonnative ubiquitin chain synthesis
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generate a thioether C-terminus that can be conjugated to another diUB bearing a free C-terminus
by treating with a yeast DUB YUH1. The two parts are combined for E2-catalyzed UB chain
assembly to generate tetra UB chains with a thioether linkage. Such a process can be repeated to
generate higher order of UB chains.
Non-enzymatic reactions such as thiol-ene coupling (Scheme 1-3B) have been used to
assemble diUB and UB chains where a photoinitiator was used to induce radical formation on the
thiol group of the Cys side chain. 108 Other researchers have been utilizing copper-catalyzed click
chemistry (Scheme 1-3C) to make ubiquitin chain analogues.

109-111

Despite of the convenience

these coupling chemistries bring, these linkages are regarded as nonnative with variations in the
atomic length of chains or orientation of two ubiquitin moieties.
1.4.2 Activity-based protein profiling by ubiquitin probes
To profile the specificity in both ubiquitin transfer process and ubiquitin chain recognition
process of define linkage, protein engineering tools have been developed to generate ubiquitin or
ubiquitin conjugates equipped with reactive functionalities. These activity-based probes, often
made available by protein engineering based on expressed-protein ligation (EPL) or unnatural
amino acid incorporation, have helped researchers understand the writing, editing and reading of
ubiquitin code.
1.4.2.1 UB with C-terminal electrophiles as probes
The C-terminus of ubiquitin can be conveniently derivatized by EPL with new
functionalities most frequently electrophiles acting as DUB traps

112, 113

. A couple of examples

described below involve generating an activated C-terminal carboxylate in the form of thioester
bond by EPL, namely, UB~MES.114 For instance, ubiquitin with a C-terminal vinylmethylester
(UB-VME, Scheme 1-4A) has been generated through UB~MES as probe to identify upregulated
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DUBSs in tumor cells or virally-infected cells. 115, 116 More recently, UB-Dha (Scheme 1-4B) with
a dehydroalanine at the C-terminus was reported to probe catalytic cysteines in ubiquitin transfer
cascade; E1, E2 and HECT E3 were able to be labelled. 117

Scheme 1-4 mono UB probes

1.4.2.2 diUB probes with Cys traps to target DUB and E3s
To understand the ubiquitin chain specificity of DUBs or E3s, diUB probes are made with
defined linkage types. Similar to the monoUB probes described in last section, a Gly to Cys
mutation is inserted so that an electrophilic trap can be created. 118, 119 Following this idea, Brik et
al synthesized linkage-specific diUB by total peptide synthesis to introduce a dehydroalanine at
the linkage site as traps for catalytic Cys residues of DUB (Scheme 1-5A) 96, 120; a linear dimer of
ubiquitin embedded with a dehydroalanine was also reported to selectively label M1-polyubiquitin
reactive DUB, OTULIN.121 Nevertheless, the linkage between distal and proximal ubiqiuitins was
also generated with click chemistry while the distal ubiquitin containing alkyne group was made
available from aforementioned EPL and azido group on proximal ubiquitin was incorporated with
genetic code expansion. (Scheme 1-5B) 122. A Michael acceptor bearing α, β-unsaturated ketone
was embedded and served as a reactive warhead towards corresponding DUBs. Furthermore,
linkage-specific triUB probes could be assembled by coupling a distal UB functionalized with a
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C-terminal α, β-unsaturated ketone linker with a Cys residue replacing a specific Lys on the diUB
(Scheme 1-5C). The triUB probe has been used to investigate the recognition of UB chains by the
DUB USP9X 123, 124

Scheme 1-5 DiUB probes for DUB chain specificity profiling
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2

DECIPHERING THE COMPLEXITY OF UBIQUITIN CHAINS: DESIGN AND
SYNTHESIS OF DI-UBIQUITIN PROBES VIA GENETIC CODE EXPANSION
Understanding the ubiquitin chain specificity in ubiquitin transfer, elongation and edition

processes proves to be essential to decipher ubiquitin code. To this end, tremendous work has been
done to generate linkage-specific ubiquitin chains but ubiquitin polymers themselves didn’t
explain much of the specificity without corresponding regulators, such as chain builders, erasers
or readers. Nevertheless, structural or biochemical studies of E2, E3 or DUB provides little
knowledge towards chain specificity if their interactions with ubiquitin chains are ignored.
2.1

Mechanism-based Di-Ubiquitin probes design
Ubiquitin transfer, chain elongation and edition can all be simplified into a three-

component event based on the molecular reaction mechanism. In these processes, an additionelimination mechanism featuring a nucleophilic attack is highlighted: for ubiquitin transfer, a
catalytic cysteine on HECT E3 will nucleophilic attack the corresponding E2~UB conjugated with
a thioester bond (Figure 2-1A). Similarly, in chain elongation process, a pre-selected lysine residue
on the acceptor UB or proximal UB will nucleophilic attack the corresponding E2~UB where Cterminus of the donor or distal UB is fully activated (Figure 2-1B) whereas in chain edition or
ubiquitin removal process, the catalytic cysteine on DUB will nucleophilic attack the amide of the
isopeptide bond (peptide bond for M1 linkage) between distal and proximal UBs (Figure 2-1C).
Taken together, the specificity implicated in these processes or reactions is determined by the intact
interactions in between these three components.
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Figure 2-1 Mechanism of ubiquitin transfer, chain elongation and removal

In this thesis, the molecular logic of linkage specificity revealed by E2, E3 and DUB is
focused. Taken E2 as an example, the ubiquitin chain elongation adapts a typical additionalelimination mechanism. Initially, donor UB is covalently bound to a particular E2 through a
thioester bond (1); the thioester bond is prone to be nucleophilic attack by an acceptor UB forming
a tetrahedron intermediate (2). (Figure 2-2) At this rate-determine step, the interaction between the
acceptor UB and E2 is crucial for recognition of these components in that E2 shall orientate
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acceptor UB and potentially select a specific lysine residue (M1, K7, K11, K27, K29, K33, K48,
K63) that facilitates the nucleophilic attack by its ε-amino group. Following this logic, it was
hypothesized that if one can snapshot this transient tetrahedron intermediate (2) by trapping it with
stable mimics, the intact interactions between acceptor UB and its corresponding E2, donor UB
and acceptor UB, donor UB and E2 can be captured and visualized simultaneously.

Figure 2-2 Tetrahedron intermediate formation in ubiquitin chain elongation

In these interfaces imprinted by this snapshot, the interaction between acceptor UB and E2
is the most important yet hard to capture, given that it reveals the direct molecular evidence that
E2 orientate acceptor UB to ensure linkage specificity but it was believed the binding affinity
between acceptor UB and E2 is low to mM level. In addition, the interaction between the two UB
moieties also potentially plays a role to maintain chain specificity especially those ubiquitin chains
adopting a “closed” conformation (K48, K11 for instance, Chapter 1.2.1). Nevertheless, reported
crystal structures of donor UB~E2 suggest a flexible conformation featuring E2 links to the long
tail of donor UB C-terminus; a third component (either an acceptor UB, HECT E3 or substrate) is
critical to solidate the conformation of donor UB~E2 into a rigid complex of three to facilitate
ubiquitin chain elongation or ubiquitin transfer to substrates. This hypothesis serves as the
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guideline for diUB probe design in the thesis and will be further discussed in later sections (Chapter
4.1).
Some criterion need to meet when design mimics for protein-protein interaction (PPI)
mapping: firstly, the protein complex should be chemically or enzymatically accessible with biocompatible ligation reactions; additionally, protein complex should be rigid and stable for
characterization and further analysis; most importantly, with bio-organic tools available, this
mimic should be as close resemblance to native one as possible with the least perturbance in
structures or intact interfaces. To this end, a novel complex featuring a disulfide linkage (4) or a
thioether linkage (6) is designed (Figure 2-3B). To probe the chain specificity of E2 (as an example
shown in Figure 2-3B), HECT E3 or DUB, a di-UB probe with defined linkage (3) embedded a
G76C mutation is utilized in such a way that the inserted cysteine at the linkage site can serve as
a reactive warhead to form a disulfide bond with corresponding E2; therefore, the resulting threecomponent complex (4) is a stable mimic for the transient tetrahedron intermediate (2). Compared
to 2, the mimic counterpart 4 is very close to native with the catalytic thiol on E2 three-atom away
from the catalytic center for this addition-elimination reaction; the isopeptide bond formed
between the C-terminus of donor UB and ε-amino group on the lysine of the acceptor UB is
completely native.
Nevertheless, this diUB probe (3) can be easily converted into an electrophilic trap by thiol
elimination; the resulting diUB probe featuring a dehydroalanine next to the catalytic center for
addition-elimination reaction (4) can be used as a 1,4-Michael addition acceptor to report any
catalytic thiol on E2/HECT E3/DUB that recognize this ubiquitin chain type. Notably, the carbon
for thiol addition is only two-atom away from the native catalytic center.
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Figure 2-3 Mechanism-based design of Di-ubiquitin probes
In a retro-synthetic perspective, the question narrows down to the accessibility of linkagespecific UB dimer with a thiol reactive group (3). Although several synthetic or semi-synthetic
approaches have been summarized in Chapter 1.4, a more convenient method via genetic code
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expansion has been investigated. (Scheme 2.1). Instead of introducing the chain specificity
(selected lysine to be modified) by SPPS, the amber codon position for unnatural amino acid
incorporation ensures the specificity of UB chain assembly by nature; unlike GOPAL approaches
that requires tenuous steps of protection and deprotection, the 1-amino-2-thiol- reactive
functionality is directly introduced in the form of synthesis-compatible unnatural amino acid,
namely Nε-L- thiaprolyl-L-lysine (L-ThzK), by an pre-engineered pyrrolysinyl tRNA synthetase
derived from directed evolution.
Upon the UAA incorporation, a deprotection reaction is used to convert UB-ThzK into
UB-CysK to reveal the 1-amino-2-thiol reactive motif; CysK is not incorporated directly because
1-amino-2-thiol functionality was reported to react with intrinsic pyruvate to form an adduct. 104,
125

Donor UB is engineered as an intein fusion so that a reactive thiolester can be readily formed

after the intein cleavage. Finally, the native linkage of an isopeptide bond is achieved through
native chemical ligation.

2.2

Resolving the linkage specificity: genetic code expansion approach
Unnatural amino acid (UAA) incorporation into proteins via genetic code expansion has

greatly expanded the structural diversity and chemical reactivity of the functionalities on a protein
scaffold.

126-129

UAA-incorporated proteins have become powerful tools for biological studies -

they can generate precise posttranslational modification patterns130 or be site-specifically attached
with customarily made chemical probes to enable photocrosslinking131, biorthogonal labeling132,
photocaging133 or enzymatic profiling capacities134 on the proteins.
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Scheme 2-1 Synthetic scheme for diUB probe
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In principle, unnatural amino acid incorporation hijacks the native translational machinery
for nascent peptide synthesis and transform the ambor stop codon (UAG) into a sense codon by
introducing another orthogonal pair of aminoacyl-tRNA and aminoacyl-tRNA synthetase (RS) to
insert UAA at UAG position. (Figure 2-4)135, 136 Notably, this extra pair of aminoacyl-tRNA and
its cognate synthetase shall be orthogonal to intrinsic ones in a way that the extra synthetase
introduced can charge pre-selected UAA onto its corresponding tRNA exclusively from any of the
20 natural ones and vice versa. To this end, a general strategy for generating orthogonal
tRNA/aminoacyl-tRNA synthetase pairs in bacteria makes use of orthologues from archaeal
bacteria or eukaryotic organisms considering that some prokaryotic tRNA/aminoacyl-tRNA

Figure 2-4 UAA incorporation through ambor codon suppression
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synthetase pairs do not cross-react to any significant degree with their eukaryotic counterparts, as
a result of differences in tRNA identity elements, primarily in the acceptor stem and variable
arm137. Therefore, the first orthogonal E. coli tRNA/synthetase pair to be generated from archaeal
bacteria was derived from the tyrosyl pair from Methanococcus jannaschii135. However, the widetype Mj tyrosol-tRNA synthetase can only take tyrosine as a cargo, hence extra mutations around
the amino acid binding region on the Mj tyrosol-tRNA synthetase need to be introduced to kill the
original activity of charging wide-type tyrosine and compensate it with capacity of desired
unnatural amino acid. The mutations are selected from several rounds of positive and negative
selection of a tyrosol-tRNA synthetase library randomizing the key residues for amino acid
recognition128, 138; this directed evolution approach was awarded Nobel Prize in Chemistry in 2018.
The first generation of UAAs in the GCE toolbox is mainly tyrosine derivatives inserted
by Mj tyrosol-tRNACUA/synethetase pair. Recently, a large number of lysine derivates were
reported to be successfully incorporated into different organelles by Methanosarcina barkeri or
Methanosarcina mazei pyrrolysyl-synthetase (Pyl-RS)/ pyrrolysyl tRNA (Pyl-tRNA) pair. (Figure
2-5) 139-143

3

4

Figure 2-5 Unnatural amino acids that have been genetically encoded in proteins to date.
Notably, incorporation of lysine derivatives has largely enriched GCE toolbox to
investigate post-translational modifications on lysine, such as acetylation, methylation and
ubiquitination.130 A more convenient GCE method to generate native and site-specific ubiquitin
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chain was reported utilizing δ-thiol-Nε-(p-nitrocarbobenzyloxy)-L-lysine into acceptor UB
(Figure 2-6).

104

Unlike SPPS or GOPAL methods discussed in Chapter 1.4.1, genetic code

expansion featuring ambor codon suppression ensures incorporation at a pre-defined position for
ubiquitin elongation. Furthermore, direct insertion of a protected 1-amino-2-thiol functionality
bypasses several steps of protection and deprotection because other amines don’t require pretreatment in native chemical ligation.

Figure 2-6 GCE approach for traceless and site-specific diUB synthesis

2.3

Incorporation of L-Thiazolidine Lysine (L-ThzK) into Ubiquitin via GCE
Similarly, L-thiazolidine-L-lysine was reported to be incorporation into protein via GCE to

facilitate orthogonal protein labeling.125 L-thiazolidine-L-lysine is also a 1-amino-2-thiol
functionality precursor that can be condensate with Cyanobenzothiazole.(Figure 2-7). In this
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paper, Chin lab has reported an evolved Pyl-RS to incorporate L-ThzK bearing which contains
three programmed mutations: A267S, C313V, M315F and one nonprogrammed mutation D344G.
Consequently, n this thesis, we decided to utilize this UAA incorporation to generate acceptor UB
bearing a 1-amino-2-thiol motif for native chemical ligation (NCL).(Scheme 2-1) Notably, this
inserted thiol serves both as a nucleophilic trigger for NCL and a reactive warhead for enzymes
conjugation or profiling. (Figure 2-3)

Figure 2-7
Incorporation of L-ThzK for bioorthogonal labelling: original reported
application for ThzK incorporation

2.3.1 Synthesis of Nε-L- thiaprolyl-L-lysine (L-ThzK)
Instead of preparing ThzK from N-Boc-L-Lys-OMe 11,

125

we chose N-Boc-Lys(Cbz)-

OH 9, a cheaper starting material to begin our synthesis (Scheme 1B). We first methylated 3 to
generate protected Lys methylester 10 and then deprotected Cbz group on 4 by hydrogenation to
afford 11. We then coupled 11 with L or D form of Boc-thiazolidine-4-carboxylic acid 12 to afford
Boc and methylester protected ThzK (13a and 13b). We either removed all the protecting group
on 13a and 13b to generate the free acid forms of L/Z-ThzK-OH (7a and 8a) or only removed the
Boc group to generate the methylester forms of ThzK (ThzK-OMe, 7b and 8b). Through this
procedure, we achieved an overall yield of 25% for the synthesis of ThzK-OMe and similar yields
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for ThzK-OH. Nevertheless, the final product was purified with HPLC (preparative-C12 column).
The usage of ThzK-OMe will be discussed in the next section. Detailed procedure of synthesis
with full characterization is in Chapter 2.6.

Scheme 2-2 ThzK synthesis
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2.3.2 Incorporation of L-Thiazolidine-L-Lysine(L-ThzK) into Ubiquitin
Genetic code expansion relies on extra vectors encoding orthogonal tRNA and tRNA
synthetase to compensate additional UAA incorporation. To express ubiquitin incorporating LThzK, ubiquitin gene featuring a stop codon (TAG) at K11, K48 or K63 position was inserted into
original pBAD mother vector kindly provided by Chin lab; the very vector also encodes
Pyrrolysinyl tRNACUA. Additionally, pBk vector also from Chin lab encoding engineered L-ThzK
Pyrrolysinyl synthetase was co-transformed into DH10B cells. L-ThzK at 1 mM was added when
the cell culture reached the OD 0.6. Detailed procedure of protein expression is documented in
Chapter 2.6.
Following the described protocol, 1 liter of UB expression would yield ~6 mg of UB with
L-ThzK incorporation after purifying the 6×His-tagged UB by a Ni-NTA affinity column (Figure
2-8). Although UBK11ThzK was able to be purified and well characterized by mass spectrum
(MALDI), unfortunately, the yield was not decent enough to provide sufficient protein for the
following steps. A few modifications on the original reported protocol was examined including
increasing UAA concentration to 5mM, increasing induction temperature from 30 degree to 37
degree, changing vectors (pCDF vector encoding ubiquitin gene or pBk vector encoding ThzKPylS), but the yield didn’t increase a lot.

2.4

Methyl ester form of Unnatural amino acids that increases incorporation Efficiency
in GCE
Previously Wang and co-workers demonstrated the beneficial effect of acetoxymethyl ester

form of a Tyr UAA analogue in enhancing its incorporation into GFP in mammalian HEK293
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Figure 2-8 Genetic code expansion for L-ThzK protein expression
(A) Scheme for L-ThzK incorporation into UB yielding UBK11ThzK (B) Coomassie gel of fractions in NiNTA affinity purification. F: Flow-through; L Lysis buffer wash; W1, W2 Wash buffer wash; E1, E2
Elution buffer wash with a UB band at around 11kD. (C) MALDI-LP shows the correct molecular weight
(11161), corresponding to calculated molecular weight (11154)

cells.

144

Liu’s group reported the use of methylester form of L-ThzK to achieve good yield of

incorporation into UB in E. coli cells.

145, 146

We suspected the L- and D-ThzK-OH in their free

carboxylic acid forms could have poor membrane permeability to the E coli cell and so they would
not be readily available for incorporation to the target proteins. We thus tried methylester forms of
L and D-ThzK-OMe (7b and 8b) for ThzK incorporation into K11 of UB.
To test the incorporation efficiency, we first used the engineered L-ThzKRS125 to express
UB with L-ThzK incorporated at K11 of UB. We supplied the cell culture with 1 mM L-ThzK-

10

OH (7a) UAA and found 1 liter of UB expression would yield ~6 mg of UB with L-ThzK
incorporation after purifying the 6×His-tagged UB by a Ni-NTA affinity column (Figure 2-9A).
We also attempted D-ThzK-OH (8a) incorporation into UB with ThzKRS originally engineered
for L-ThzK incorporation and found a similar yield of UB expression (Figure 2-9B). We repeated
the experiment for GFP incorporation and found the incorporation efficiency of either L- or DThzK-OH into GFP was much lower than that of ε-Boc-Lys (BocK) when wt PylRS of the
Methanosarcina mazei (Mm) or Mb origin were used for protein expression (Figure 2-10A and
Figure 2-10B). When we used the engineered ThzKRS derived from Mb PylRS for incorporation,

Figure 2-9 Incorporating L- or D-ThzK into UB at K11 with the free acid or methylester forms
of the UAA
(A) UB expression with Mb ThzKRS and L-ThzK-OH. The Coomassie stained gel of protein samples from the flow
through of the Ni-NTA column (F), lysis buffer wash (L), twice wash buffer wash (W1 and W2), and twice elution
buffer wash (E1 and E2) were shown. (B) UB expression with ThzKRS and D-ThzK-OH. (C) UB expression with
ThzKRS and L-ThzK-OMe. (D) UB expression with ThzKRS and D-ThzK-OMe. (E), (F) and (G) MALDI spectra
of UB with L-ThzK, D-ThzK and Lys incorporated at K11, respectively. Calculated MS for each specie: 11154,
11154, 11039. The difference in the MW of UB with ThzK and with Lys incorporated is 115, matching the addition
of the thiazolidine carboxylate to the Lys residue at K11.
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the yield of L/D ThzK incorporation into GFP was still low as judged by the weak bands of GFP
on the SDS-PAGE gel stained with Coomassie blue (Figure 2-9C). BocK UAA is known for its
high efficiency of incorporation into various proteins by wt PylRS so such a result was expected.
147

Correspondingly, the GFP fluorescence from the cell culture also showed significantly higher

fluorescence for incorporating BocK into GFP with wt PylRS of Mm and Mb origin. In contrast,
the GFP fluorescence with L or D-ThzK-OH incorporation was low across the board with either
wt PylRS or ThzKRS (Figure 2-9D).
We supplied 1 mM L-ThzK-OMe to the cell culture to compare the efficiency of
incorporation with the same concentration of ThzK-OH. We found we could express an average
of 33 mg of L-ThzK-incorporated UB from 1 liter of cells while the yield of L-ThzK incorporation
into UB with L-ThzK-OH was only 6 mg (Figure 2-9A and 2-9C). The results of protein expression
were consistent among three trials. We found similar improvement when we compared the yield
of D-ThzK incorporation into UB with D-ThzK-OMe and D-ThzK-OH. The methylester form of
UAA yielded 37 mg of UB from 1 liter of cell culture while the free acid form yielded 6.3 mg of
UB, 17% of the methylester UAA (Figure 2-9B and 2-9D). The correct incorporation of ThzK into
UB using L- or D-ThzK-OMe was confirmed by MALDI spectrometry comparing the difference
of the MWs of UB with either ThzK or Lys incorporated (Figure 2-9E, 2-9F and 2-9G).
Our work showed that the yield of ThzK incorporation into UB could be increased by as
much as 6-fold with the use of the methylester form of the UAA. With the use of the same tRNA
synthetase and E coli strain for incorporation, the enhancement of the yield is most likely due to
the improved membrane permeability of the methylester forms of the UAA to E coli cells
comparing to the free acid forms of the UAA.
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Figure 2-10 Comparing the yield of BocK and ThzK incorporation into GFP with wt PylRS and
ThzKRS.
(A) Using wt Mm PylRS to incorporate various forms of UAA into GFP. Efficiency of incorporation was evaluated
based on the intensity of the GFP band on the gel. (B) Using wt Mb PylRS to incorporate various forms of UAA into
GFP. (C) Using ThzKRS engineered for L-ThzK incorporation to measure the yield of GFP expression with various
UAA. (D) The intensities of fluorescence signals from cells expression GFP using various UAA and tRNA
synthetase pairs. The results are the average of three trials.

Here we carried out detailed comparison of the yields of L- and D-ThzK incorporation
between the methylester and free acid forms of the UAA and found ThzK methylester could
enhance UAA incorporation by 6 folds. We suggest the methylester forms of UAA could benefit
the incorporation if the free acid forms of UAA give poor yields. Our results may help to revive
the interest in some UAA-engineered tRNA pairs by enhancing the permeability of UAA in its
methylester form. On the other hand, there is only moderate increase of BocK incorporation into
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GFP when the BocK-OMe form is used comparing to the free acid form (Figure 2-10D). So if the
free acid form of UAA is incorporated well into proteins, further enhancement in yield with the
methylester form is not obvious.

2.5

Building up ubiquitin chains: native chemical ligation (NCL)

2.5.1 Finalize acceptor UB: transforming UBThzK into UBCysK
Incorporated thiazolidine needs to be deprotected in order to reveal the 1-amino-2-thiol
functionality. For this purpose, methoxyamine works as a competitor for the aldehyde group148,

Figure 2-11 Conversion from UBThzK into UBCysK
(A) Scheme for deprotection reaction. (B) HPLC chromatogram for purifying UBCysK, retention time: 16-17 min (C)
MALDI-LP shows the molecular weight of UBThzK 11158 (calculated 11155) (D) ESI shows the molecular weight
of UBCycK 11145 (calculated 11142)
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that rapidly reacts to form an oxime, conveniently releasing the captured peptide or protein. 149, 150
Therefore, methoxyamine is extensively used in SPPS for protein synthesis when several peptides
need to be ligated together sequentially, such as erythropoietin151 and modified histones152, 153.
Detailed protocol is described in Chapter 2.6. After the reaction, the molecular weight reduces 12
Da, indicating the full conversion from UBThzK into UBCysK. (Figure 2-11)
To confirm the full conversion of UBThzK into UBCysK, a labeling assay utilizing a thiolreactive reagent, Biotin-Maleimide was performed. Theoretically, UBCysK after the deprotection
can react with Biotin-Maleimide whereas UBThzK cannot. Indeed, the molecular weight increase
detected by MALDI-LP was expected. (Figure 2-12)

Figure 2-12 Biotin labeling assay for UBCysK
(A) UBCysK after the deprotection reveal a thiol group that can react with Biotin-Maleimide. (B) MALDI-LP shows
the correct molecular weight of Biotin conjugated UB 11673. (calculated 11667)
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2.5.2 Construct donor UB: generating a reactive C-terminus
The intein carries out protein slicing, a unique auto-processing event where it excises itself
out from a larger precursor polypeptide through the cleavage of two peptide bonds. This
rearrangement usually occurs post-translationally for protein maturation.154, 155 In addition, inteinmediated protein splicing is spontaneous; it requires no external factor or energy source, only the
folding of the intein domain.
Hijacking this natural feature, intein was utilized by protein chemists intensively centered
around the cleavage and/or formation of peptide bonds.156, 157 Among them, the most frequently
used ones are intein-facilitate tag-free protein expression and purification158, in vitro protein
synthesis like expressed protein ligation. (EPL)159. (Figure 2-13) Ubiquitin probes bearing an
electrophilic C-terminus for DUB profiling described in Chapter 1.4.2 (Scheme 1-4) was generated
based upon intein-mediated EPL.

Figure 2-13 Protein modification using streamlined EPL.
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Following the same strategy, tagged-free donor Ub with a thioester C-terminus was
generated as such: ubiquitin-intein fusion protein was expressed in E. Coli and purified with chitin
beads which has strong affinity to intein tag. After washing out unbound impurities in cell lysate,
the ubiquitin was eluted out with 200 mM MesNa to generate Ub~MesNa, a C-terminus activated
ubiquitin to facilitate native chemical ligation. Elution with DTT yields ubiquitin with a native Cterminus. The detail protocol derived from a reported streamlined EPL procedure by Muir lab159
is descried in Chapter 2.6. However, due to the low binding capacity of chitin beads compared to
the scale of protein expression (2L), remaining UB-Intein fusion protein was found in flowthrough, wash1 and wash2 buffers for the chitin affinity purification; as a result, another round of
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Figure-2-14 Donor UB~MesNa formation
(A) Mechanism for UB~MesNa formation mediated by intein. (B) Coomassie gel for chitin affinity purification:
F1,W1,W2,E1,E2 Flow through, Wash buffer washes and elutions for the first-round binding
F2,F3,F4,W3,W4,W5,W6 Flow through, Wash buffer washes for the second-round binding (C) HPLC chromatogram
for purifying UB~MesNa with retention time: 16-17 min (D) MALDI-LP shows the molecular weight of UB~MesNa
8634.38 (calculated molecular weight 8632.0)

purification was performed to immobilize all UB-Intein fusion protein upon MesNa cleavage.
(Figure 2-14)

2.5.3 Build up ubiquitin chains: native chemical ligation
Native chemical ligation reaction (NCL) involves reacting a C-terminal peptide thioester
with an N-terminal cysteinyl peptide to produce a native peptide bond between the two
fragments.160, 161 This reaction has considerably extended the size of polypeptides and proteins that
can be produced by total synthesis and has also numerous applications in bioconjugation, polymer
synthesis, material science, and micro- and nanotechnology research.162, 163 Notably, an N,S-acyl
shift is the key note in NCL featuring an intramolecular rearrangement. (Scheme 2-1)
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The targeted linkage-specific di-UB can be conjugated together with native chemical
ligation with both acceptor ubiquitin and donor ubiquitin available. Firstly, a pilot reaction between
Ub~MesNa and a synthetic HA peptide featuring an N-terminal Cysteine was performed. (Figure
2-15A) If the native chemical ligation works, the donor UB can be labelled with HA tag therefore
can be detected on western blot blotting on HA antibody. As a result, in a panel of ligation
reactions increasing the input of the Cys-HA peptide, UB~MesNa could be labeled successfully
showing on Coomassie and Western blot (Immunoblotting: HA) (Figure 2-15B and C).
Nevertheless, the molecular weight of labelled ubiquitin with a C-terminal HA tag could be detect
by MALDI-LP, which corresponded to the calculated one (Figure 2-15D).
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Figure 2-15 NCL between UB~MesNa and Cys-HA peptide
(A) Reaction between UB~MesNa and Cys-HA peptide yields C-termial HA-tagged UB after N, S-acyl shift.
(B) (C) Coomassie and Western blot (Immunoblotting HA) shows the reaction results: 3A1 Cys-HA peptide only,
3B1 UB~MesNa only, 3C1 to 3 E1 1,1.5,2 equivalency of Cys-HA peptide added; the right panel is a duplicate.
(D) MALDI-LP shows the correct molecular weight of UB-HA: 9704. (calculated molecular weight: 9695)

Now that the full conversion from UBThzK to UBCysK and the reactivity of Ub~MesNa
towards NCL were both confirmed by two aforementioned pilot reactions, the reaction between
UBCysK and UB~MesNa was investigated. (Scheme 2-1 and Figure 2-16A) To optimize the
conditions for NCL, the reaction was monitored in a time-course manner and the product diUB
was detected in the Coomassie gel. Additionally, the acceptor UB prepared from GCE features a
His×6 tag followed by an HA tag, can be detected with Western blot immunoblotting on HA,
whereas donor UB, made from intein-mediated EPL, is tagged-free. Interestingly, the NCL
reaction between engineered donor UB and acceptor UB is very fast (Figure 2-16B): at 0 hour,
some diUB could be detected while at 2-hour time point, the reaction was complete. The fast
reaction manner can be explained by the high concentration of both components (1-2 mM) to
facilitate an effective nucleophilic attack by the thiol on UBCysK to the C-terminus of Ub~MesNa,
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which is the rate-determine step in NCL; the intramolecular rearrangement of N, S- shit is
spontaneous and fast. Nevertheless, to fully-consume acceptor UBCysK and drive the reaction to
complete, another equivalent of UB~MesNa was added at 2-hour time point. After 4 hours, the
total depletion of acceptor UB was observed on Coomassie gel (Figure 2-16B); the trace amount
of acceptor UB band on gel could be due to the misincorporation of UAA with a wide-type lysine
incorporated and no reactivity towards NCL. Lastly, a couple of mass spectrometry approach were
used to characterize prepared diUB. The diUB in the ligation reaction mixture was detect by
MALDI-LP to show the correct total molecular weight; whereas the linkage specificity was
implicated by an in-gel digestion followed by LC-MS analysis (Figure 2-16C and 16D). After
trypsin digestion, a branched peptide TLTGK(CG)TITLEVEPSDTIENVK should be expected
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Figure 2-16 NCL between acceptor UBCysK and donor UB~MesNa
(A) Reaction between UBCysK and UB~MesNa yields chain-specific diUB (K11-diUB as an example)
(B) Coomassie gel of NCL reaction in a time-course manner; CysK: acceptor UBK11CysK (11.5kD) SR: donor
B~MesNa (8.5kD) 0, 2, 4, o/n: reaction mixture at 0, 2, 4 hour and overnight. Formation of diUB (19.5KD)
(C) MALDI-LP shows the correct molecular weight of diUB 19643 (calculated molecular weight 19632)
(D) LC-MS shows the correct peptide molecular weight after trypsin digest. The molecular weight of a branched
peptide with Lys11 conjugated to a GlyCys motif through isopeptide bond is detected as 2505.2061; the calculated
molecular weight of this peptide is 2505.2752.

where K represents the Lys11 and (CG) stands for the isopeptide modification on Lys11 position
which indicated K11-linkage specificity.
Notably, excess amount (2.0 to 3.0 equivalent) of donor UB over acceptor UB was used.
A couple of reasons explain the optimized stoichiometry of this reaction. Acceptor UB prepared
through GCE requires several steps of UAA synthesis, protein expression and purification; thus,
consuming acceptor UB by adding more donor UB is overall efficient in large amount of diUB
production. In addition, the excess amount of tag-free donor UB can be easily removed through
Ni-NTA affinity purification (Figure 2-17) Since acceptor UB has an N-terminal His and HA tag,
diUB with little unreactive mono acceptor can be enriched in the elute of Ni-NTA purification and
prone to further purification.

22

Figure 2-17 Ni-NTA affinity purification of diUB
F: Flow-through, monomeric donor UB in excess
L: Lysis buffer wash
W1, W2: Wash buffer wash
E1, E2 Elution buffer wash, enriched diUB with little monomeric acceptor UB and a highermolecular impurity band

After Ni-NTA affinity purification to remove donor UB in excess, additional step is needed
to further polish the purity of diUB. At this point, size-exclusion, cation/anion-exchange
chromatography were all investigated for this purpose. Ubiquitin is a very small protein; dimeric
UB is only 9 kD bigger than monomeric UB. As a result, size-exclusion chromatography was not
very effective to separate them (Results are not shown). Nevertheless, cation-exchange prevails
anion-exchange in separating diUB from other impurities because ubiquitin featuring several
positively charged amino acid residues such as lysine or arginine charges better in cation forms
(Figure 2-18A). In addition, a pH-scouting approach is used to further optimize the condition
suitable for diUB separation (Figure 2-18B). In conclusion, diUB can be purified most with anionexchange chromatography with a 10-75% salt gradient at pH 5.0 (Figure 2-18C and D).
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Figure 2-18 Ion-exchange chromatography for diUB purification
(A) Anion-exchange chromatography (pH=8.0) gives little separation of diUB from other impurities.
(B) Cation-exchange chromatography (pH=6.0) gives little separation of diUB from other impurities.
(C) Cation-exchange chromatography (pH=5.0) gives good separation of diUB, the peak with retention time 37 min
was the correct one containing diUB. Gradient: 8-40% in 20 min following by 40-80% in 40 min
(D) Coomassie gel staining showing the separation of cation-exchange chromatography (C), which suggested the
fraction 36-41 were the right ones containing diUB.

2.6

Conclusion
To summarize this chapter, DiUB with defined linkage was prepared through native

chemical ligation between an acceptor UB incorporating the 1-amino-2-thiol functionality and a
donor UB featuring a reactive thiolester at C-terminus. To this end, acceptor UB and donor UB
were made in parallel: acceptor UB was generated with genetic code expansion approach to sitespecifically incorporate thiazolidine lysine containing a protected 1-amino-2-thiol moiety whereas
donor UB was produced with intein-mediated expressed protein ligation.
In a long synthetic route shown in Scheme 2-1, yield in each step is very crucial to maintain
a streamline of diUB production for whatever purpose. Thereby, tremendous endeavor had been
made to improve the yield for each step and eventually methylated Thiazolidine lysine (ThzKOMe) can be obtained and purified with HPLC in gram-level. This facilitate the methylated version
of UAA incorporation with a yield of 40-60 mg/1L media culture. After deprotection, HPLC

25

purification and lyophilization, 15-20 mg of lyophilized UBCysK was collected from the same
prep subject to native chemical ligation. Nevertheless, two rounds of binding and elution with
chitin beads ensures a massive production of UB~MesNa after HPLC and lyophilization. Lastly,
15-20 mg of UBCysK will generate around 15 mg diUB after affinity purification, thus around 35 mg diUB after cation-exchange. This streamline of diUB production renders it possible for large
diUB probe synthesis for activity-base protein profiling and for diUB-E2/E3 conjugates formation
to resolve their structures.
2.7

Material and Methods

2.7.1 Unnatural amino acids synthesis
Synthesis of methyl N6-((benzyloxy)carbonyl)-N2-(tert-butoxycarbonyl)-L-Lysinate (10)
Synthesis of ThzKOH and ThzKOMe was based upon previous reported protocols with
some modifications125, 164, 165. To a 250 mL round-bottom flask, Boc-Lys(Cbz)-OH (3, 7.23g, 19.0
mmol) was added then dissolved with DMF 40 mL, followed by potassium carbonate (5.25g, 38.0
mmol). The solution was cooled to 0o C and iodomethane (1.05 ml, 24.7 mmol) was added
dropwise. The temperature was allowed to raise to room temperature and the reaction was stirred
under N2 for overnight. The reaction mixture was analyzed with thin layer chromatography
(Hexane: EtOAc = 1:1, Rf = 0.6), then dissolved in ethyl acetate (50 ml) and extracted twice using
water (100 mL) to remove excess DMF. The organic layer was then extracted using brine (100
mL) and the combined organic layers were concentrated to dryness and purified using column
chromatography (Hexane: EtOAc = 1:1). The resulting oil is 6.5 g with a yield of 87%. NMR
analysis is in agreement with previous reports. 1H (400 MHz, CDCl3): δ = 1.37-1.59 (13H, m,
includes Boc, Hγ, Hδ), 1.62-1.90 (2H, m,Hβ), 3.17-3.21 (2H, q, J = 6.3, CH2NHCbz), 3.63 (3H,
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s, CO2Me), 4.09-4.14 (1H, m, Hα). 5.02(2H, s, CH2Ph), 5.09-5.14 (2H, m, NHBoc and NHCbz),
7.26-7.36 (5H, m, CHAr). MS: m/z (ESI+): 295.16 [M+H-Boc]+, calculated MS: 295.17.
Synthesis of methyl (tert-butoxycarbonyl)-L-Lysinate (11)
Methyl N6-((benzyloxy)carbonyl)-N2-(tert-butoxycarbonyl)-L-Lysinate (10, 1.0 eq) was
dissolved in ethyl acetate (40 mL) and ethanol (10 ml) to which palladium on carbon (10%, 0.39
mmol) was added and hydrogen was bubbled through the solution three consecutive times to
promote efficient reduction. Completion of the reaction was monitored using TLC analysis
(Hexane: EtOAc = 1:1) showing the disappearance of starting material. A final ninhydrin stain
(Dichloromethane: Methanol = 9:1) confirmed reduction of the carboxybenzyl group to a free
amine. The palladium was removed by filtration through a pad of Celite and the product was
concentrated to dryness and the resulting crude oil 4.2g, 98% (crude yield) was used for the next
step without further purification. 1H (400 MHz, CDCl3) : δ = 1.46-1.84 (15H, m, contains Boc,
Hγ, Hδ, and NH2), 1.57-1.89 (2H, m, Hβ), 2.66 (2H, t, J = 6.7, CH2NH2), 3.79 (3H, s, CO2Me),
4.35-4.89 (1H, m, Hα), 5.63 (1H, d, J = 7.6, NHBoc). MS: m/z (ESI+): 261.06 [M+H]+, calculated
MS: 261.18.
Synthesis of methyl Nε-Boc-L-thiazolidine-N-Boc-L-Lysinate (13a)
N-boc-L-thiazolidine-4-carboxylic acid (1.0 eq.) was dissolved in dichloromethane (40ml).
Next, 4-Dimethylaminopyridine (DMAP, 0.5 eq.) was added followed by subsequent addition of
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, 1.2 eq.). After an hour of stirring at 0o C,
Boc-L-Lysine Methylester (previously dissolved in 5 mL DCM) was added dropwise. Completion
of the reaction was monitored using TLC analysis (Hexane: EtOAc = 1:1, iodine stain, Rf = 0.4).
The mixture was diluted with dichloromethane (50 mL) and extracted with 1M HCl (50 ml) and
brine (50 ml). The organic fractions were dried with magnesium sulfate and concentrated to
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dryness to give the crude product. The product was purified using column chromatography hexane:
ethyl acetate = 3:1 to yield white foam 3.7 g, 48%. 1H (400 MHz, CDCl3): δ = 4.67 (1H, t, J=6.7,
αCH), 4.85 (1H, d, J=10.2, CHaHb), 4.33 (1H, d, J=10.2, CHaHb), 3.93 (1H, t, J=6.7, αCH), 3.543.24 (1H, m, CHa’Hb’), 3.19-3.15 (3H, m, CH2 and CHaHb’), 1.76-1.70 (2H, m, CH2), 1.45-1.42
(2H, m, CH2), 1.42-1.25 (20H, m, including Boc and CH2). MS: m/z (ESI+): 498.20 [M+Na]+,
calculated MS: 498.22.
Synthesis of methyl Nε-Boc-D-thiazolidine-N-Boc-L-Lysinate (13b)
Same as 13a except starting with N-boc-D- thiazolidine-4-carboxylic acid. Yield: 3.4g,
44%.1H (400 MHz, CDCl3): δ = 4.66 (1H, t, J=6.7, αCH), 4.75 (1H, d, J=10.3, CHaHb), 4.34 (1H,
d, J=10.3, CHaHb), 3.91 (1H, t, J=6.7, αCH), 3.42-3.20 (1H, m, CHa’Hb’), 3.21-3.11 (3H, m, CH2
and CHaHb’), 1.64-1.60 (2H, m, CH2), 1.45-1.42 (2H, m, CH2), 1.41-1.21 (20H, m, including
Boc and CH2). m/z (ESI+): 498.20 [M+Na]+. calculated MS: 498.22.
Synthesis of Nε-Boc-L-thiazolidine-N-Boc-L-Lysine (14a)
Methyl N-Boc-L-thiazolidine-N-Boc-L-Lysinate 13a (10.5 g, 22.0 mmol, 1 eq) was
dissolved in THF:H2O (3:1, 150 mL); LiOH·H2O (1.9 g, 44.0 mmol, 2 eq) was added in room
temperature and the reaction was stirred overnight. Completion of the reaction was monitored
using TLC analysis (Hexane: EtOAc = 1:1, iodine stain, Rf = 0.2). The reaction mixture was then
diluted with EtOAc (50 mL) and water (50 mL). The aqueous layer was acidified to pH 4 using
5% aqueous citric acid solution and then extracted with EtOAc (~ 50 mL). The combined organic
fractions were washed with brine, dried (Na2SO4) and filtered. The filtrate was concentrated under
reduced pressure, to give Nε-Boc-thiazolidine-N-Boc-L-Lysine as a colourless gum 9.27g, 91%.
The crude product was used for deprotection without further purification. m/z (ESI+): 462.30
[M+H]+, calculated MS: 462.23.
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Synthesis of Nε-Boc-D-thiazolidine-N-Boc-L-Lysine (14b)
Same as 14a except starting with Nε-Boc-D-thiazolidine-N-Boc-L-Lysinate (13b). Yield:
8.71g, 86%. m/z (ESI+): 498.08 [M+Na]+, calculated MS: 498.22.
Synthesis of Nε-L-thiazolidine-L-Lysine (7a)
Nε-Boc-L-thiazolidine-N-Boc-L-Lysine (14a, 1 eq.) was dissolved in 1,2-dioxane and
stirred at room temperature. 4M hydrogen chloride in dioxane was added dropwise and the reaction
was allowed to stir overnight, which resulted in formation of a white precipitate. Excess solvent
was removed through evaporation and the crude was further purified using ether precipitation
(3700 rpm, 10 min, 4o C). The crude product was further purified with RP-HPLC (Phenomenex
Preparative Jupiter 10

Proteo 90Å column, 10 mL/min) 0-30% (H2O/Acetonitrile) in 30 min.

Retention time: 7-8 min. The fractions containing product were collected and lyophilized to
dryness. 2.13 g, 40.6%. 1H (400 MHz, D2O) δ = 4.55 (1H, t, J=6.9, αCH), 4.39 (1H, d, J=10.3,
CHaHb), 4.29 (1H, d, J=10.3, CHaHb), 3.91 (1H, t, J=6.0, αCH), 3.58-3.26 (1H, m, CHa’Hb’),
3.21-3.13 (3H, m, CH2 and CHaHb’), 1.86-1.79 (2H, m, CH2), 1.49-1.44 (2H, m, CH2), 1.44-1.25
(2H, m, CH2) m/z (ESI+): 262.10 [M+H]+, calculated MS: 262.12(Figures S1).
Synthesis of Nε-D-thiazolidine-L-Lysine (8a)
Same as 7a except starting with Nε-Boc-L-thiazolidine-N-Boc-L-Lysine (14b). Yield:
1.84g, 37.2%. 1H (400 MHz, D2O) δ= 4.53 (1H, t, J=6.9, αCH), 4.62 (1H, d, J=10.1, CHaHb),
4.38(1H, d, J=10.1, CHaHb), 3.76 (1H, t, J=6.0, αCH), 3.58-3.26 (1H, m, CHa’Hb’), 3.20-3.14
(3H, m, CH2 and CHaHb’), 1.76-1.65 (2H, m, CH2), 1.54-1.33 (2H, m, CH2), 1.33-1.25 (2H, m,
CH2) m/z (ESI+): 262.10 [M+H]+, calculated MS: 262.12. (Figures S2).
Synthesis of methyl Nε-L-thiazolidine-L-Lysinate (7b)
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Same as 7a except starting with Nε-Boc-L-thiazolidine-N-Boc-L-Lysinate (14a). Yield:
1.21 g, 57%. 1H (400 MHz, D2O) δ= 4.51 (1H, t, J=6.9, αCH), 4.65 (1H, d, J=10.3, CHaHb), 4.40
(1H, d, J=10.3, CHaHb), 3.84 (1H, t, J=6.0, αCH), 3.77 (3H, s, OCH3), 3.60-3.28 (1H, m,
CHa’Hb’), 3.22-3.15 (3H, m, CH2 and CHaHb’), 1.82-1.64 (2H, m, CH2), 1.60-1.43 (2H, m,
CH2), 1.43-1.31 (2H, m, CH2) m/z (ESI+): 276.0 [M+H] +, calculated MS: 276.14. (Figures S3).
Synthesis of methyl Nε-D-thiazolidine-L-Lysinate (8b)
Same as 7a except starting with Nε-Boc-D-thiazolidine-N-Boc-L-Lysinate (14b). Yield:
1.45 g, 74%. δ= H (400 MHz, D2O) 4.53 (1H, t, J=6.9, αCH), 4.57 (1H, d, J=10.3, CHaHb), 4.47
(1H, d, J=10.3, CHaHb), 3.75 (3H, s, OCH3), 3.54 (1H, t, J=6.0, αCH), 3.67-3.33 (1H, m,
CHa’Hb’), 3.33-3.20 (3H, m, CH2 and CHaHb’), 1.79-1.64 (2H, m, CH2), 1.61-1.42 (2H, m,
CH2), 1.42-1.29 (2H, m, CH2) m/z (ESI+): 276.0 [M+H]+, calculated MS: 276.14. (Figures S4).
2.7.2 Protein expression and purification of Ubiquitin K11ThzK
Protein expression was based upon reported protocols with some modifications125, 166.10
mL overnight culture of E.coli DH10B cells carrying either pBK-ThzKRS or pBk-MmPylRS and
pMyoUbK11TAG pylT was inoculated into 2L 2XYT containing 100 μg/mL Ampcillin and 20
μg/mL tetracycline. The cells were incubated at 37 ºC in 220 RPM shaker. 1 mM of unnatural
amino acid (7a, 7b, 8a or 8b) was dissolve in water and pH of the solution was adjusted by 2M
NaOH to 8. When the OD of the culture reached 0.6, the UAA solution was added and the culture
was allowed to grow at 37 C for another half to one hour until the OD reached approximately 0.8.
Then arabinose (0.02%, final concentration) and IPTG (1 mM final concentration, optional) were
added and the culture was incubated in 30 ºC shaker (200 RPM) for overnight.
The cells were harvested with centrifugation (5,500 RPM, 30 min) and the pullets were
resuspended with 50 mL NTA lysis buffer (50 mM phosphates, 300 mM NaCl, 10 mM imidazole,
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pH=8.0) in which 1 mg/mL lysozyme, 100 μg/mL DNaseI, 1 mM PMSF, Roche protease inhibitor,
5 mM DTT were added. The resuspended cells were incubated on ice for at least half an hour
before being sonicated at 4 ºC for 30 min. The extract was clarified by centrifugation (30 min,
12,000 RPM, 4 ºC). 2 mL of Ni-NTA beads (Qiagen) were added to the extract and the mixture
was incubated with agitation for overnight at 4 ºC in a cold box. The beads were transferred to a
gravity column and flow through (F) was collected. Then the beads were resuspended in 30 mL
NTA lysis buffer (L), followed by 20 mL, 10 mL NTA wash buffer (50 mM phosphates, 300 mM
NaCl, 20 mM imidazole, pH=8.0, W1 and W2). Finally, protein was eluted from the beads with
NTA elution buffer (50 mM phosphates, 300 mM NaCl, 250 mM imidazole, pH=8.0, 5 mL each
time for five times and collected as E1, E2, E3, E4 and E5). The protein concentration was
measured by BSA assay (Bio-rad) and the yield of protein expression with each UAA incorporated
was determined with three repeats of the same protocol and materials. The fractions in protein
purification collected as F, L, W1, W2, E1, E2, E3, E4, E5 was analyzed by 4-15% SDD-PAGE
and visualized with Coomassie staining.
2.7.3 SfGFP Assay of UAA incorporation
pPylsfGFPY151TAG was transformed into electrocompetent DH10B cells with
pBkThzkRS, Mm pBkBocLys, and Mb pBkBocLys respectively. The cells were plated onto LB
agar supplemented with 15 μg/ml tetracyclin and 50 μg/ml kanamycin (cells containing the
pBkThzKRS plasmid was plated onto 100 μg/ml ampicillin instead of kanamycin). After overnight
incubation at 37 ⁰C, a colony from each plate was inoculated into 5 mL LB supplemented with its
respective antibiotics (Tet15 with either Kan50 or Amp100) and let grow overnight in 37 ⁰C
shaker. 500 μL of the starter culture was inoculated into 20 mL of LB supplemented with its
respective antibiotics and arabinose with a final concentration of 0.2 %w/v. The cultures were
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allowed to grow to OD600 = 0.5, at which point 2.5 mL of each culture was aliquoted into culture
tubes. A final concentration of 2 mM L-ThzK-OH, L-ThzK-OMe, D-ThzK-OH, D-ThzK-OMe,
L-BocLys-OH, L-BocLys-OMe were added to its respective cultures in triplicates. The cultures
were incubated in the 37 ⁰C shaker overnight to allow for protein expression. The cultures were
harvested by spinning at 5,000 rpm for 10 minutes and washed twice with 2 mL PBS. The cells
were pelleted again and resuspended in 2 mL PBS and 100 μL of each culture was spotted onto a
Greiner Bio-One 96 well clear bottom plate. Florescence of the sfGFP were taken by excitation at
485 nm and emission at 510 nm using a SpectraMax M5 plate reader.
2.7.4 Transforming UBThzK into UBCysK
After protein expression and NTA affinity purification, UBThzK was dialyzed into
dialysis buffer (25mM Tris, 50mM NaCl, 1mM DTT, pH=8.0) then lyophilized. Then
lyophilized protein was rebuffered in 3-5 mL “rebuffer buffer” (6M Guanidium chloride, 200
mM phosphate buffer, pH=7.2). 400 mM methoxyamine was then added and pH was adjusted to
4.0; the resulting solution was incubated at 37oC for 4-5h. The protein is then purified with
HPLC (Semi-preparative C12 column at flow rate 4 mL/min, 15-80% Acetonitrile/water + 0.1%
TFA). The fractions were analyzed by MALDI-LP or ESI-POS while the correct fractions were
combined and lyophilized.
2.7.5 Intein-mediated donor UB preparation
E.Coli BL21(DE3) transformed with pTBX1-Ub(ΔG76)-Intein was grown in 1L LB
containing 100 µg/mL ampicillin at 37°C until OD600 reached to 0.6159. Protein expression was
induced by addition of 1 mM IPTG for overnight at 20°C. After harvesting the cells by
centrifugation (8000g, 30 min), the cell pellets were resuspended by Chitin lysis buffer (20mM
sodium phosphate, 200 mM NaCl, 1mM EDTA, 1mM TCEP, 20 µM PMSF, pH=7.2) and
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sonicated on ice for 30 min to lysis the cells. The crude cell lysate was collected after centrifugation
(12000RPM, 1 hour) to remove cell debris. Then regenerated chitin beads were added to the crude
cell lysate and incubate at 4°C cold box overnight. The flow-through was collect next day and the
chitin beads were washed twice with Chitin wash buffer (20mM sodium phosphate, 200 mM NaCl,
1mM EDTA,1mM TCEP, pH=7.2) until the Chitin elution buffer (20mM sodium phosphate, 200
mM NaCl, 1mM EDTA,10 mM TCEP, 200 mM MesNa, pH=7.2) was treated to the resin. Chitin
beads were incubated the elution buffer for 2 days at room temperature on a rotating platform
before the elution was collected. The resin was treated with Chitin elution buffer again to make
sure all the UB-intein fusion protein was eluted out. Flow-through (F) and Chitin wash buffer
washes (W1, W2) and Chitin elution buffer (E1, E2) were analyzed by SDS-PAGE coupled with
Coomassie staining. The remaining UB-intein fusion protein was subjected to rebinding with newregenerated chitin beads for a second round of elution. All the elutions were analyzed by MALDILP or ESI-POS and then HPLC purified HPLC (Semi-preparative C12 column at flow rate 4
mL/min, 10-70% Acetonitrile/water + 0.1% TFA). The correct fractions were characterized by
mass spectrometry again and lyophilized to dryness.
2.7.6 Native chemical ligation to generate diUB
UBCysK (3.8 mg, 225 nmol) was dissolved in 100 µL ligation buffer (200 mM sodium
phosphate pH 7.1, 6 M GdnCl, 100 mM mercaptophenylacetic acid (MPAA), 60 mM TCEP)104.
In parallel, UB~MesNa (9.8 mg, 453 nmol) was dissolved in 200 µL ligation buffer and 100 µL
was added to the UBCysK solution at 0 hour. The reaction was stirred at room temperature under
N2 for 2 hours before the second portion (100 µL) of UB~MesNa was added. The resulting reaction
was stirred for another 2 hours and UBCysK, UB~MesNa, reaction mixture at 0, 2, 4 hours were
analyzed by SDS-PAGE coupled with Coomassie staining. The reaction was quenched with 1M
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TCEP (pH=8.0) and then diluted into 3 mL high salt buffer (200 mM sodium phosphate pH 7.1, 6
M GdnCl.) The diluted solution was dialyzed into 1×PBS buffer supplemented with 1 mM DTT.
The next day, the dialyzed solution was treated with Ni-NTA resin and incubated on a rotating
platform at 4°C cold box overnight. The unreactive UB~MesNa or hydrolyzed donor UB was
enriched in the flow-through (F), NTA lysis buffer wash (L), NTA wash buffer washes (W1,W2)
before the desired diUB with little unreactive mono aceeptor UB was collected in NTA elution
buffer (E1,E2,E3,…). The fractions during the NTA affinity purification were analyzed by SDSPAGE coupled with Coomassie staining. The elutions containing diUB product were combined
and dialyzed into cation-exchange buffer A (50 mM ammonium acetate, pH=5.0, 1 mM 2mercaptoethanol) and further purified by Bio-Rad GNC in a 15-80% gradient of cation-exchange
buffer B (50 mM ammonium acetate, pH=5.0, 500 mM sodium chloride, 1 mM 2mercaptoethanol). The fractions were analyzed by SDS-PAGE gel and then diUB product was
collected and dialyzed into NTA dialysis buffer (25 mM Tris, 50 mM NaCl, 1 mM DTT).
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3

Targeting the unknown ubiquitin chain regulators:
Activity-based protein profiling by Di-Ubiquitin probes

Activity-based protein profiling (ABPP) utilizes interdisciplinary approaches including
organic synthesis, protein engineering, sometimes isotope labeling coupling with cutting-edge
mass spectrometry analysis to design active-site-directed covalent probes to interrogate specific
subsets or families of enzymes in complex proteomes and to provide the basis for a quantitative
readout of the functional state of individual enyzmes.167, 168 Compared to in vitro protein activity
assay, ABPP probes subsets of enzymes with more accurate assessment of their function states in
cells and tissues to have a more clear understanding in terms of protein expression and posttranslation modifications. Initially, the functions of serine hydrolases169, 170, cysteine proteases171,
172

and kinase173 were elegantly probed and investigated with ABPP, revealing the distinct reactive

mechanisms and substrate specificity. Most recently, ABPP was used widely for enzyme activity
profiling including DUBs 174, enzymes associated with cancer or microbe. 175-177

3.1

Generating thiol-reactive Di-Ubiquitin probes through dethiolation
DiUB synthesized by UAA incorporation and native chemical ligation bears a cysteine

near the linkage site of acceptor and donor UB. Notably, this very cysteine serves at first as the
nucleophile that initiates the native chemical ligation and it is not redundant or doesn’t require
desulfurization given that it can be utilized as a reactive warhead to probe the chain specificity of
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known E2, E3, DUBs through forming tri-protein complex followed by structural analysis or
unknown ubiquitin regulators through activity-based drug profiling design. (Scheme 3-1)

Scheme 3-1 Activity-based protein profiling with diUB-Dha
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In this design, diUB-Cys (3) prepared is transformation into diUB-Dha (5) featuring a 1,4Michael acceptor, which can covalently capture any E2, E3 or DUBs that can recognize and react
with diUB with pre-defined linkage. After treating diUB-Dha (5) with lysed proteasome, the
linkage-specific ubiquitin chain regulators will be linked to the probe through a stable thiolether
bond. In addition, since acceptor UB is His×6 tagged and HA tagged, diUB probe along with
conjugated UB chain modifiers can be enriched and immobilized with streptavidin beads. Upon
tryptic digestion, the signature peptides can be detected by LC-MS and the intact protein can be
identified.
Converting cysteine embedded in a peptide or protein into an electrophilic trap,
dehydroalaine, proves to be an effective way for orthogonal protein labeling178, protein
conjugation179, 180 and activity-based protein profiling117, 181. Several bio-compatible approaches
were reported to fulfill this task.165 In general, the thiol residue, inserted at the position of interest,
is first transformed into leaving groups, which upon elimination, yield Dha. (Figure 3-1)
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Figure 3-1 Methods to introduce dehydroalanine (Dha)
Methods to introduce dehydroalanine (Dha) as a ‘tag’ to proteins. The position of interest is typically activated by
conversion to a Dha precursor followed by its elimination to Dha. Protein taken from PDB: 1N2E

To this end, 2,5-dibromohexandiamide or α,α’-Dibromoadipyl(bis)amide, DBHDA or
DBAA, was used to fulfill the conversion due to the reported convenient dethiolation approach
mediated by it.117,

165, 182, 183

First of all, DBAA was synthesized following reported

protocol165.(Scheme 3-2) Gram-level of final product was obtained with full characterization by
1

H-NMR and ESI-POS.

Scheme 3-2 Synthesis of α, α’-Dibromoadipyl(bis)amide (DBAA)

With DBAA available, the dethiolation was carried out according to reported protocol.
Like previously described, DBAA is prone to be nucleophilic attacked by the thiol on diUB-Cys
(3) yielding in DBAA adduct on diUB (3a). (Figure 3-2) This adduct can undergo another
intramolecular nucleophilic attack to form a five-member ring containing sulfur cation
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intermediate (3b). Now with a good leaving group generated, 3b can yield to dehydroalanine
product (5) via β-elimination.

Figure 3-2 DiUB dethiolation mechanism via DBAA

The reaction was analyzed by offline LC-MS. The diUB-Cys (3) has a molecular weight
of 20485, which corresponded to the calculated molecular weight 20484. (Figure 3-3) After the
incubate diUB-Cys with DBAA at 37°C for 4 hours, the reaction mixture was analyzed by LCMS yielding 20450, which also corresponded to the calculated molecular weight 20450. Notably,
the mass loss of 34 after the dethiolation was detected by the LC-MS before and after the
reaction, indicating the success of conversion.
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Figure 3-3 ESI-POS shows the correct molecular weight of diUB before and after dethiolation.

A biotin labeling assay was performed to validate the formation of Michael acceptor. If the
conversion from cysteine to dehydroalanine is successful, the diUB-Dha probe should react with
Biotin bearing a terminal thiol (Figure 3-4A). Indeed, the diUB-Dha was able to be labeled by
Biotin forming diUB-Biotin that can be detected on Western blot blotting on Streptavidin. (Figure
3-4B) Notably, diUB-Dha itself in Lane A was free of Biotin and Biotin-PEG-SH itself in Lane C
only had small molecular (less than 10 kDa) bands, which both serve as negative control for this
assay.
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Figure 3-4 Biotin-PEG-SH labelling assay for diUB-Dha
(A) Biotin-PEG-SH reacts with diUB-Dha to form an adduct onto diUB chain.
(B) Western blot blotting on Streptavidin to show the Biotin-labelled diUB with a correct MW band around 20 kDa.

3.2

Verifying the reactivity of Di-Ubiquitin probes with known regulators
To confirm the conversion from diUB-Cys (3) to diUB-Dha (5) and its reactivity towards

various linkage-specific UB regulators, K48-diUB-Dha was synthesized at first given that there
are several known E2, E3, or DUB that can target specifically to K48 chains or at least reported to
mediate K48 chains. After the reaction and characterization (Figure 3-3), K48-diUB-Dha was
dialyzed into low salt buffer to remove small molecular reagents. The labelling reaction carried
out at pH 7.6 which was around physiological pH to prevent site reactions from other nucleophiles
on protein, such as lysine side chain. Additionally, EDTA (0.1mM) was added to remove any trace
amount of metal ions that are predicted to oxidize thiols into disulfide bond. The reaction can be
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monitored by both Coomassie gel and Western blot blotting on HA given that acceptor UB is
equipped with an N-terminal His-HA tag.
For this purpose, two E2s (Ubch5b, Ubch7) and two HECT E3s (HUWE1, NEDD4) were
selected and reacted with K48-diUB-Dha. Ubch5b belongs to Ube2D subfamily that is reported
to build up promiscuous UB chains whereas Ubch7 (Ube2L3) only transfer charged UB to a
cysteine residue on HECT or RBR E3s without ubiquitin chain elongation activity. HUWE1 is
known to mediate K6, K48, K63 chains on substrate while NEDD4 extends K63 chains.
Surprisingly, K48-diUB-Dha was not reactive to Ubch5b, Ubch7, HUWE1 or NEDD4 based upon
Coomassie gel and WB results. (Figure 3-5)

Figure 3-5 K48-DiUB-Dha reacts with E2s and E3s
(A) SDS-PAGE with Coomassie staining shows the reactions between K48-diUB-Dha and various colored-coded
E2s or E3s.
(B) Western blot (IB: HA) shows the reactions between K48-diUB-Dha and various colored-coded E2s or E3s.
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While Ubch7 and NEDD4 inert to K48-diUB are expected, Ubch5b may need extra
components, for example, E3s, to extend UB chains. In this regard, E2-25K (Ube2K) is reported
to elongate K48 UB chains in the absence of an E3184, thus it is the next subject to try with K48diUB-Dha labeling. Another possible reason is due to the reactivity of catalytic cysteines on E2 or
E3s. The nucleophilicity of cysteines on them is effective enough to facilitate transthiolation from
UB~E2 or UB~E3 but may not be trapped to an 1,4-Michael acceptor at physiological pH.
Nevertheless, the double bond of dehydroalanine embedded on the isopeptide backbone of diUB
is next to an amide. As a result, the electron density of this double bond is increased by forming
an enamine due to resonance, rendering it less electrophilic for less reactive thiols.
Considering the reactivity, DUBs with a catalytic cysteine that mediates amide bond
cleavage in UB chain should be more reactive to diUB-Dha. Indeed, labeling reactions were
observed when incubating K48-diUB-Dha with various DUBs that were known to cleave K48
linkages.(Figure 3-6) OTUB1 has been reported to mediate exclusively K48 chains86 whereas
OTUB2 is also known to mediate several linkage UB chains including K48 ones185,

186

.

Interestingly, as recently reported, the roles of both OTUB1 and OTUB2 are heavily implicated in
cancer187,

188

. Clinical studies have associated elevated OTUB1 expression with high grade,

invasiveness and metastasis in several tumor types including lung, breast, ovarian, glioma, colon
and gastric. In addition, OTUB1, as one of the most abundant DUBs in cell, displays a catalyticindependent non-canonical activity where it inhibits the transfer of UB onto protein substrates by
sequestration of E2.86 Similarly, OTUB2 was reported to promote cancer metastasis via Hippoindependent activation of YAP and TAZ, two transcriptional regulators that play important roles
in tumorigenesis.
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Figure 3-6 Reaction between K48-DiUB-Dha with DUBs
(A)(B) Coomassie gel and Western blot (IB: HA) results suggest K48-DiUB-Dha was able to react with OTUB1
and OTUB2.
(C)(D) Coomassie gel and Western blot (IB: HA) results suggest K48-DiUB-Dha was able to react with isoT but not
PLPro.
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Two more DUBs were tested against K48-DiUB-Dha, namely, IsoT and PLPro. Other than
OTUB1 and OTUB2, IsoT belongs to USP superfamily that is known to mediate promiscuous UB
chains due to lack of a well-defined S’ site. In particular, isoT (USP5/USP14) specifically
dissembles unanchored K48 and linear UB chains from the proximal end.189, 190 In addition, a viral
DUB, the severe acute respiratory syndrome (SARS) Coronavirus Papain-like Protease (PLPro)191,
that cleaves ISG15, a two-domain UB-like protein and K48 UB chains respectively was selected.
Indeed, after the reaction, the diUB-labelled OTUB1, OTUB2, isoT can be successfully
detected by SDS-PAGE gel coupled with Coomassie staining and Western blot immunoblotting
HA on diUB. (Figure 3-6). Notably, DUBs alone and diUB itself didn’t reveal the diUB-DUB
band as expected. However, PLPro was not able to react with K48-DiUB-Dha. This founding
actually matches the observation reported in a paper co-published by Ovaa, Huang, Lima191 where
SARS-PLPro was treated with monoUB-ABP, distal-DiUB-ABP and in-between-DiUB-ABP
made from SPPS. As a result, distal-DiUB-ABP reacted well with PLPro while monoUB-ABP
reacted fairly but in-between-DiUB-ABP (the one that similar to our K48-DiUB-Dha) was inert to
PLPro. They provided an explanation to this in the paper based upon the crystal structure of SARSPLPro with several UB binding sites including S1, S1’, S2, S3. They claimed that PLPro possibly
binds the in-between-DiUB-ABP via S2-S1, preventing it from binding and reacting via S1-S1’
interactions.
Lastly, as a negative control, DUBs were incubated with DiUB-Dha pretreated with βMercaptoethanol (BME). Presumably, BME featuring a terminal thiol will block the reactivity of
DiUB-Dha by forming an adduct bound with thiolether. The result was as expected(Figure 3-7);
no DUB could react with BME-pretreated DiUB probe, proving the reactivity of DiUB-Dha is due
to the electrophilicity of Dehydroalanine motif with a Michael acceptor.
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Figure 3-7 DUBs react with K48-DiUB-Dha pretreated with BME
(A) Reaction between DiUB-Dha with BME yielding an BME adduct therefore blocks its reactivity
(B) OTUB1 and OTUB2 were able to react with K48-DiUB-Dha but not BME pretreated K48-DiUB-Dha
suggested by Western blot (IB: HA)
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3.3

Conclusion
To summarize this chapter, DiUB-Cys prepared by unnatural amino acid incorporation and

native chemical ligation was readily transformed into an activity-based probe by dethiolation. The
generated DiUB-Dha was able to react with UB regulators, especially linkage-specific DUBs with
different efficiency. DiUB embedded with dehydroalanine was synthesized with SPPS by Brik
group and the DUBs were probed120; our work provided a more convenient way to circumvent
time and effort consuming SPPS and enable large-scale of diUB production available for protein
profiling with recombinant UB regulators or cell lysate. Notably, due to the unique position of the
1,4-Michael acceptor in the diUB backbone, the electrophilicity was moderate and prone to be
reactivate to stronger thiols but not all UB regulators featuring a catalytic cysteine. This could
bring an advantage as an activity-based probe that selectivity is ensured both by the linkage
specificity and the reactivity of the handle. Nevertheless, for some DUBs like PLPro that cannot
be properly labelled, UB chain probes with longer length or branched architecture can be a future
direction. Furthermore, some regulators may require additional components to be full reactive;
probing the diUB-Dha with cell lysate should be able to “fish-out” more reported and even more
intriguingly unknown linkage-specific UB regulators in their “active” mode. Last but not the least,
the linkage types can be expanded to atypical chains such as K6, K27, K29, K33 given that a lot
of their regulators (E3s, DUBs) have not be discovered yet.

48

3.4

Material and Method

3.4.1 α,α’-Dibromoadipyl(bis)amide (DBAA) synthesis
DBAA was synthesized according to a reported protocol with some modifications128, 165.
Adipic acid (5.00 g, 35.1 mmol) was added to a 500 mL round bottom flask and suspended in
thionylchloride (25.0 mL, 207 mmol). The flask was equipped with a condenser and the reaction
was heated to reflux (open to air, bath temp 80 ºC). After 30 minutes at reflux, all adipic acid had
dissolved. The reaction was stirred for an additional 60 minutes at reflux and then cooled to room
temperature. CCl4 (20 mL) was added to the reaction followed by NBS (18.7 g, 82 mmol). The
reaction was stirred vigorously and 2 drops of HBr (48% aq.) was added by pipette. The reaction
was heated to reflux, again open to air. The reaction gradually turns from red to black over the
course of an hour. After 2 hours at reflux, the reaction was cooled to room temperature and then
to 0 ºC. The mixture was stirred at 0 ºC to ensure all succinimide had precipitated. The solid was
removed by filtration. Et2O (20 mL) was used to rinse and complete the filtration. The filtrate was
concentrated under reduced pressure to give a thick, dark red liquid. In a 500 mL round bottom
flask, 50 mL of NH4OH (25% aq.) was cooled to 0 ºC. The crude acid chloride was added dropwise
over 20 minutes to the ammonia solution with rapid stirring. After the addition was complete, the
reaction was stirred vigorously at 0 ºC for 1 hour. The bis-amide product precipitated from the
reaction mixture. The dark solid was isolated by filtration and partially dried. The product was
purified by triturating in MeOH/H2O: The solid was suspended in H2O (100 mL) and MeOH (100
mL) and heated to 60 ºC. The mixture was stirred rapidly at 60 ºC for 30 minutes. After this time,
the mixture was cooled to room temperature. The resulting white solid (a mixture of meso and d/l
diastereomers) was isolated by filtration and washed with MeOH (200 mL). The product (22) was
dried under high vacuum (3.6 g, 37%). 1H NMR (400 MHz, DMSO): δ = 1.75-2.08 (4H, m,
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CH2CH2), 4.28-4.36 (2H, m, 2 Å~ CHBr), 7.30 (2H, s), 7.69 (2H, s) (2 Å~ NH2). 13C NMR (100
MHz, DMSO): (both diastereomers reported), δ = 32.5, 32.6 (CH2CHBr), 48.2,48.5 (CH2CHBr),
169.87, 169.92 (C=O). LRMS m/z (ESI+): 324.9 [M+Na]+.

3.4.2 DUB expression
OTUB1, OTUB2, IsoT(USP5) and PLPro plasmid were purchased from Addgene. Upon
transformation into E.Coli BL21(DE3) cell, OTUB1,OTUB2 and PLPro were expressed according
to a standard His tag protein expression protocol.

84, 191, 192

IsoT was expressed based upon a

standardized GST protein expression protocol except for an additional “heat shock” step to activate
the molecular chaperones to correctly fold the protein. 193, 194

3.4.3 Dethiolation with DBAA
Dethiolation was carried out following reported protocol with some modifications.165 cAbDiUB-Cys was first reduced with DTT to remove any contaminant disulfide: DTT (1.2 mg, 7.8
umol) was added to 500 uL of DiUB-Cys (c = 1 mg/mL in 10 mM PBS, pH 8.0) and shaken at
room temperature for 15 minutes. After this time, the protein solution was passed through a PD
minitrap (GE Healthcare), previously equilibrated with 10 mM PBS (pH 8.0), eluting with 1 mL
of the same buffer. The reduced protein was stored on ice until needed. DBAA (1.2 mg, 3.3 μmol)
was added to a 1.5 mL plastic tube as a solid. An 875 μL aliquot of the reduced DiUB-Cys prepared
above (c = 0.5 mg/mL in 10 mM PBS, pH 8.0) was added to the same tube. No DMF was used in
this reaction. The reaction was shaken at room temperature for 1 hour, and then 37 °C for 4 hours.
The reaction was then cooled to room temperature and precipitated DBAA was removed by
centrifugation (1 min, 16K g).
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3.4.4 Labeling reaction with DUBs
DiUB-Dha was dialyzed into 50 mM Tris, pH=7.5, 25 mM NaCl containing 0.1 mM
EDTA; DUB was dialyzed into 50 mM Tris, pH=7.5, 25 mM NaCl containing 0.1 mM EDTA and
then pretreated with 1mM TCEP upon reaction. 15 μM DiUB probe was incubated with 20 μM
DUB at 37 ºC for 5 hours and the reaction was analyzed with SDS-PAGE coupled with Coomassie
staining and western blot immunoblotting on HA.
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4

DEFINING THE TOPOLOGIES OF UBIQUITIN CHAINS: THE LINKAGE
SPECIFICITY OF E2S, E3S OR DUBS REVEALED BY DI-UBIQUITIN PROBES

Protein-protein interactions (PPIs) are critical regulatory events in physiology and
pathology, and they represent an important target space for pharmacological intervention.
However, protein-protein interactions are normally hard to capture due to the weak binding affinity
between their interfaces and dynamic topologies during protein trafficking.

195

To this end,

Chemical cross-linking, along with yeast two-hybrid, fluorescence resonant energy transfer
(FRET),

and

co-immunoprecipitation

have

become

and characterization of protein-protein interactions.196,

197

important

tools

for

detection

In particular, chemical crosslinking

helped to determine the interfaces between two entangled proteins by increasing the binding
affinity and stabilizing transient protein complex. 129, 198 So far, mechanism-based design of a tricomponent protein complex proves to be novel approach to decipher weak and transient proteinprotein interactions.

4.1

E2 at work: Probing UBE2S chain specificity with K11 Di-Ubiquitin
It has been known a decant ago that K11 UB chains are critical cell-cycle regulators in

human cells.44 These K11-linked chains are synthesized during mitosis by the E3 anaphasepromoting complex (APC/C) and its E2s Ube2C and Ube2S.35, 199, 200 Working together, these
enzymes ubiquitinate mitotic regulators, such as cyclin B, securing, HURP as a degradative
signal.201 In this regards, inhibition K11 polyubiquitination blocks mitotic progression in Xenopus,
Drosophila and humans as a result of inaccurate cell division and tumorigenesis. However, the
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molecular basis of generating K11 chains by APC/C and its E2s was largely unclear when we tried
to stress this question by diUB probe.
Previously, Rape group had proposed a model of the interactions between donor UB and
Ube2S

202

; Ube2S was known to mediate K11 chains on mitotic substrates. According to NMR

mapping and docking, a noncovalent hydrophobic binding of donor UB is required for Ube2S
activity (Figure 4-1A). Therefore, some key residues were identified through site-mutagenesis.
However, authors also claim that the acceptor binding was too transient to be detected by NMR,
independently of whether the donor ubiquitin had been linked to the Ube2S activate site or not.202
Later on, to validate the donor UB~Ube2S interaction, a stable linkage between them was made
through disulfide bond to replace the original unstable thioester bond; the structure of the
crosslinked heterodimer was solved and reported (Figure 4-1B)203. As a result, the structure
contains an interface between Ube2S and UB in trans that resembles the earlier model in general

Figure 4-1 Donor UB and Ube2S interaction
(A) NMR-derived docked model. Donor UB in blue and Ube2S in orange.
(B) Crystal structure (PDB: IZDN) of donor UB and Ube2S linked with disulfide. Donor UB (dark green) in trans
and a backside binding UB (light green) in cis. Ube2S in orange.
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terms but differs in detail in that the crystallographic interface is more hydrophobic. Notably, UB
in NMR-derived docked model was claimed to be donor UB but in crystal structure, was a backside
binding UB in trans. The disulfide bound UB was in cis, which later on was reported as a
autoinhibition component for E2s.204 Still, no acceptor UB binding was discussed in the paper.
As discussed in Chapter 2.1, to correctly place both donor UB and acceptor UB on Ube2S
with direct evidence on structure, it was hypothesized that if the transition state that donor UB and
acceptor UB bind simultaneously to Ube2S (2) can be captured by stable protein complex (1), the
detailed intact interfaces should be resolved. (Figure 4-2)

Figure 4-2 Tri-protein complex design to mimic transition state of UB chain elongation
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Forming disulfide bond between two proteins or inside one protein is naturally occurring205,
206

and also frequently used for biochemist. To generate disulfide bond, any reducing reagents are

prohibited. Firstly, CuCl2 was used as an oxidative reagent. However, the resulting products were
a mixture of UB, Ube2S homodimer and UB-S-S-Ube2S.And the reaction took over two days to
reach equilibrium. (Data not shown) Thereby, 5,5'-dithiobis-(2-nitrobenzoic acid) or DTNB
(Ellman’s reagent)207 was chosen to generate heterodimeric protein complex. Thiols react with this
compound, cleaving the disulfide bond to give 2-nitro-5-thiobenzoate (TNB−), which ionizes to
the TNB2− dianion in water at neutral and alkaline pH. This TNB2− ion has a yellow color.(Figure
4-3) In addition, this reaction is rapid and stoichiometric, with the addition of one mole of thiol
releasing one mole of TNB. The TNB2− is quantified in a spectrophotometer by measuring the
absorbance of visible light at 412 nm, using an extinction coefficient of 14,150 M-1 cm−1 for
dilute buffer solutions, and a coefficient of 13,700 M−1 cm−1 for high salt concentrations, such
as 6 M GdnCl or 8 M urea.208, 209

Figure 4-3 Mechanism of Ellman's reagents to form disulfide bond

To probe Ube2S linkage specificity, recombinant Ube2S (UBC domain, residue 1-156)
was first prepared in large scale; this excludes a flexible 66-residue C-terminal extension which
cannot be crystalized.203 Additionally there are two cysteine (C98 and C118) in Ube2S UBC
domain, thus the non-catalytic cysteine was mutated to methionine (C118M). Then Ube2S
(UBCdomain) (17 kD) was expressed with an N-terminal His-SUMO tag (17.5 kD); after affinity
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purification, the tag was cleaved by SUMO deubiquitiase Ulp1

210, 211

. The cleaved Ube2S is

subjected to affinity purification aided by ATKA Fast Protein liquid chromatography and further
polished by anion-exchange chromatography to yield homogeneous Ube2S (C118M) UBC domain.
(Figure 4-4)
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Figure 4-4 Expression and Purication of Ube2S (C118M) UBC domain
(A) Ube2S construct: His-SUMO-Ube2S (C118M) fusion protein upon cleavage by Ulp1
(B) Expression of Ube2S in BL21(DE3) cells and affinity purification of fusion protein. (F: Flow-through; W1, W2:
NTA-wash buffer wash; E1, E2: NTA-Elution buffer elution
(C) NTA-Affinity purification to separate cut Ube2S and His-SUMO tag by AKTA FPLC.
(D) Anion-exchange purification to purify Ube2S as a tag-free protein.

Next, the disulfide bond formation was carried out to conjugate Ube2S UBC domain to
diUB probe bearing a thiol at the isopeptide site. DiUB-Cys features an His-HA tag on acceptor
UB that can facilitate affinity purification; thereby untagged Ube2S was added in excess to
consume diUB-Cys to drive the reaction to completion; nevertheless, diUB-Cys probe was hard to
prepare whereas Ube2S was obtained in large quantity. Ratio of diUB-Cys and Ube2S-TNB was
investigated (results not shown) and finally 1:4 ratio was the best to consume all potential diUB
based on Coomassie staining and Western blot results. (Figure 4-5) Because both diUB-Cys and
Ube2S-TNB are around 17 kDa, it was hard to observe the completion the reaction on Coomassie
staining. Fortunately, on Immunoblotting diUB-Cys band almost disappeared at 1:4 ratio,
indicating the full conversion from diUB-Cys to diUB-S-S-Ube2S.
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Figure 4-5 DiUB and Ube2S conjugation through disulfide bond formation
(A) Conjugation reaction between UBK11CysUb and Ube2S-DTNB.
(B) Coomassie gel from the reaction mixture (Lane 1 and Lane 2) and after desalting to remove excess TNB.
(C) Western blot (IB: HA) shows the reaction mixture (Lane 1 and Lane 2) and after desalting to remove excess
TNB.

A tandem purification approach was utilized to purify the tri-protein complex. After
desalting, the crude mixture including mostly diUB-S-S-Ube2S and unreactive Ube2S, was treated
with Ni-NTA resin upon affinity purification. The beads were applied to a column and the fluid
was collected with gravity filtration. (Figure 4-6A) Notably, an affinity purification method
utilizing AKTA chromatography was investigated; however, the result was not as good. During
the wash, imidazole concentration was gradually increased from 0, 5, 20, 100, 250 mM. Under this
gradient, unbound proteins, mainly Ube2S in excess, were washed out at 0-5 mM imidazole
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Figure 4-6 Tandem purification of UBK11CysUB-S-S-Ube2S
(A) NTA-Affinity purification of UBK11CysUB-S-S-Ube2S via gravity filtration. The unbound Ube2S and the
desire product were separated by increasing imidazole concentration.
(B) Size exclusion to polish the purity of UBK11CysUB-S-S-Ube2S

whereas desired protein complex was collected in buffer containing 100 mM imidazole. The beads
then were fully stripped with 250 mM imidazole for cleaning purpose. Lastly, the complex was
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further purified by size exclusion. (Figure 4-6B)
The final product going through steps of conjugations and tandem purifications was not
decent in amount. When concentrated down, the protein complex concentration can only reach 5
mg/mL due to the limited amount. Using the automatic crystal tray set-up platform, two standard
sparse matrix screening was performed, namely JCSG-plus from Molecular Dimensions and Index
from Hampton Research; unfortunately, no protein crystal was obtained in all conditions. The yield
of the tri-protein complex was not very promising; scaling-up is needed to try more conditions
with a higher concentration of stock solution. The follow-up experiment was described in Chapter
4.3.1.

4.2

Probing HECT E3 chain specificity with Di-Ubiquitin
HECT type ubiquitin ligases (E3s) features the same catalytic cysteine in the UB transfer

process as E2s and mediates UB chains with different linkage preferences. (Figure 1-10) All HECT
E3s present the catalytic HECT domain, composed of a bulkier N-terminal lobe (N-lobe) that
contains the E2 binding domain, and a C-terminal lobe (C-lobe) carrying the catalytic cysteine.
Additionally, the two lobes are connected by a flexible hinge region that allows the C-lobe to move
around in order to facilitate UB transfer.212-214 Nevertheless, the ability to build linkage-specific
poly-UB chains seems to be an intrinsic characteristic of HECT E3s. For example, E6AP is K48
specific215 whereas NEDD4 family members are known to mediate K63 chains216. A structural
determination of the complexes formed between HECT domains, donor and acceptor UB is
challenging, due to the low affinities of the underlying interactions (high micromolar to millimolar
affinity range in vitro). To stress this question, chemical mimics of donor-HECT domain
complexes214, 217, 218 reveal that a conserved hydrophobic interface of donor UB with HECT C-
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lobe is heavily implicated in its binding; however, no structures of HECT domains with UB in an
acceptor position facing the active site have been solved. Here diUB probe conjugated with HECT
domain E3 has been proposed to capture both the donor UB and acceptor UB binding on HECT
domain.

4.2.1 HUWE1
Recent studies suggest HECT-type E3 HUWE1 regulates the stability of various cellular
substrates thus mediates several key physiological processes, including DNA replication and
damage repair, cell proliferation and differentiation, apoptosis.219-221 Interestingly, HUWE1 can
target oncoproteins, namely N-MYC, C-MYC, MCL1222, 223 but also tumor suppressor proteins
like p53224 for degradation. Importantly, HUWE1 was reported to generate K6-, K11-, K48- poly
UB chains225 and it also uses ubiquitinated substrate to seed chain extension by adding K48-linked
UB onto K63-linked UB chains formed by other E3s.226 HUWE1 crystal structure had been
solved227, 228 (Figure 4-7) However, how HUWE1 binds to donor UB and more intriguingly how

Figure 4-7 Crystal structure of HUWE1 (HECT domain) with an N-terminal extension
of dimerization region. (PDB 5LPB, Ref.228)
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HUWE1 orientate acceptor UB to achieve chain specificity were largely unknow. To this end, the
structure of UBK48CysUb conjugated with HUWE1 HECT will be very interesting and
informative to determine given that it can provide direct evidence of HUWE1 chain elongation
mechanism.
To maintain the homogeneity of disulfide product, other than the catalytic cysteine (C4341),
two extra cysteines that lies outside the enzyme was mutated to alanine. Recombinant HUWE1
(HECT domain) with an N-terminal His tag followed by an HRV-3C protease cleavage site was
expressed with BL21(DE3) cells and purified with standard Ni-NTA affinity purification protocol.
His-tag was then removed by 3C protease, yielding a tag-free version of HUWE1 (HECT domain).
(Figure 4-8)

Figure 4-8 Purification of HUWE1 HECT domain
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(A) HUWE1 HECT domain expression and purification. F: Flow-through; L: NTA-Lysis buffer wash; W1, W2:
NTA-Wash buffer wash; E1-E5: NTA-elution buffer wash.
(B) AKTA chromatography of affinity purification after His-Tag remove with 3C Protease.
(C) Coomassie gel shows the peak in (B) is the correct unbound HUWE1 HECT domain without His-tag

With tag-free HUWE1 in hand, similarly to disulfide formation between UBK11CysUB
and Ube2S, DTNB pre-activation approach was utilized to generate UBK48CysUB-HUWE1.
With a 2:1 ratio of HUWE1-TNB versus diUB-Cys, the desire tri-protein complex was readily
formed in 45 min. However, there were additional higher molecular bands detected on Coomassie
gel of the reaction mixture (Figure 4-9A, B), which suggested the additional conjugation could
happen between diUB-Cys with two internal non-catalytic cysteines. Consequently, the rest two
internal cysteines are mutated to alanine yielding single cysteine HUWE1 HECT domain with
which no additional higher molecular weight bands were detected when conjugated with diUBCys. (Figure 4-9C) Following the same purification protocol as UBK11CysUB-S-S-Ube2S, the
tandem purification delivered UBK48CysUB-S-S-HUWE1. (Figure 4-9D, E, F)
Generally, to consume 6mg purified diUB, over 20 mg tag-free HUWE1 will be needed
and thus generate over 8 mg UBK48CysUB-S-S-HUWE1 after affinity purification. In the final
step of size exclusion chromatography, 2-3 mg desired product was obtained with relatively pure
quality. This approach has been investigated over 10 repeats with yield and purity consistent in
between different diUB preps. This suggests that a streamline production, all the way from UAA
synthesis and incorporation, acceptor UB deprotection and conjugation with donor UB, diUB
coupling with HUWE1 HECT and tandem purification, has been achieved. This should provide
enough material for crystallization condition screening and structure determination.
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Figure 4-9 Reaction and purification of UBK48CysUB-S-S-HUWE1
(A) Reaction between UBK48CysUB and DTNB pre-activated HUWE1
(B) Coomassie gel shows the disulfide formation of UBK48CysUB and HUWE1 with two extra non-catalytic
cysteines. Note that there was extra higher molecular weight by-product.
(C) Coomassie gel shows the disulfide formation of UBK48CysUB and HUWE1 with only catalytic cysteine
(D) Affinity purification of UBK48CysUB-S-S-HUWE1
(E) (F) Diagram and Coomassie gel of size exclusion to further purify UBK48CysUB-S-S-HUWE1

For initial screening for crystallization conditions, the purified protein complex was firstly
concentrated as much as possible. (Figure 4-10A) According to the concentration curve in terms
of volume. The final concentration of UBK48CysUB-S-S-HUWE1 complex could reach over 10
mg/mL, which was used as stock solution for screening. Several standard sparse matrix screenings
were investigated: JCSG-plus from Molecular Dimensions, Index from Hampton Research,
Classics I from Qiagen; the temperature of incubating these plates was varied: 20 ºC or 4 ºC.
Unfortunately, no crystal was observed under these conditions, except for a couple of salt crystals.
(Figure 4-10B, C, D)
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Figure 4-10 Preliminary screening for crystallization conditions for UBK48CysUB-S-S-HUWE1
(A) The concentration of UBK48CysUB-S-S-HUWE1 can reach over 10 mg/mL.
(B) A (salt) crystal observed from JCSG-plus plate
(C) The crystal in (B) was mounted and subjected to X-ray diffraction.
(D) The X-ray diffraction pattern for crystal in (B): it turned out to be salt crystals.

As a future direction, the purity of tri-protein complex can be increased by adding two
more steps of anion-exchange chromatography to purify HECT E3 and diUB after affinity
purification respectively. In addition, the N-terminal His-HA tag on the acceptor UB could perturb
the integrity of protein complex by prohibiting potential interactions between acceptor UB and
HUWE1 or introducing non-native interferences with any of the other proteins. Therefore, a TEV
cleavage site followed by a linker sequence (GSGGS) was introduced in between the His-HA tag
and acceptor UB sequence. After the affinity purification of UBK48CysUB-S-S-HUWE1 and
before the final size exclusion step, TEV was added to cleave the tag off so that all three
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components are free of any tag. As a matter of fact, the amount of TEV needed to cleave the Nterminal tag off the acceptor UB was a lot more than common equivalency, maybe suggesting that
an additional binding of His-HA tag with the protein complex may exist and block the access of
TEV to bind to the cleavage site.

4.2.2 NEDD4-1
NEDD4-1 is one of the most studied HECT-type E3 ligase, which belongs to NEDD4
subfamily HECT E3s. Overexpression of NEDD4 has been reported in several cancer types and
downregulation of NEDD4 appears to reduce proliferation, migration and invasion of cancer
cells.229 Importantly, tumor suppressor PTEN is discovered to be the substrate of NEDD4.230
Different from E6AP or HUWE1, NEDD4 mainly generate K63-linked UB chains.

216

The

mechanism of NEDD chain specificity was partially explained by the crystal structure of donor
UB-S-S-NEED4 (Figure 4-11): the donor UB, transferred from the E2 (UbcH5B), is bound to the

Figure 4-11 Crystal strcuture of Donor UB-S-S-NEDD4 (HECT) with another non-covalent
bound UB (PDB:4BBN)
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Nedd4 C lobe with its C-terminal tail locked in an extended conformation, primed for catalysis;
such stretched conformation of donor UB appears to be mutual for a priming state of E2 or E3s.231,
232

Although in this crystal structure, a non-covalent UB bound to UBD of NEED4-1 was observed

this UB didn’t present the acceptor UB carrying the attacking lysine. Nevertheless, the authors
concluded the last 60 amino acids of HECT domain are responsible for both donor and acceptor
UB binding to determine chain specificity, however, direct evidence is missing.
There are three cysteines in NEDD4-1 with two non-catalytic cysteine and one catalytic
cysteine. With the other two cysteine mutated into alanine, NEDD4-1 was expressed with
BL21(DE3) cells with decent yield (Figure 4-12A) and a tag-free NEDD4-1 HECT domain was
obtained after a similar cleavage with 3C protease like HUWE1. (Figure 4-12B) The reaction
between UBK63CysUB and NEDD4 was successful with a ratio 1:2. (Figure 4-12C, D) Notably,
NEDD4 formed a homodimer during the disulfide formation as a by-product, indicating NEDD4
features a more reactive cysteine. So far, it has been shown that UBK63CysUB-S-S-NEDD4 can
be purified through affinity purification. (Figure 4-12E)
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Figure 4-12 Synthesis and purification of UBK63CysUB-S-S-NEDD4
(A) Protein expression and purification of NEDD4 HECT domain. (B) AKTA affinity purification of tag-free
NEED4 HECT domain after treated with 3C Protease, following by Coomassie staining. (C) (D) Reaction between
UBK63CysUB and NEDD4. (E) Affinity purification UBK63CysUB-S-S-NEDD4 (F) Size exclusion of
UBK63CysUB-S-S-NEDD4.
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4.3

Probing E2 chain specificity with Di-Ubiquitin, RING E3s and substrates
RING E3s don’t carry a catalytic cysteine that can receive the charged UB from E2 and

pass on the UB to substrate like HECT type E3s. However, RING E3 help to recruit both UB~E2
and substrate in close proximity to facilitate the substrate ubiquitination and chain elongation.
Most of the E2s cannot elongate specific chains without corresponding E3s; determine the
structure of diUB-S-S-E2 complex together with RING E3s and substrates should reveal the whole
picture of how E2 and RING E3 arrange ubiquitinated substrate as an acceptor as well as donor
UB to achieve linkage-specific UB chain elongation.

4.3.1 UBK11CysUB-Ube2S-APC/C-substrate complex
While we are making linkage-specific diUB featuring a thiol as reactive warhead, the field
is moving forward fast. Recent papers233-235 revealed the mechanism underlying the initiation of
ubiquitination on APC/C substrate by Ube2C and chain elongation on ubiquitinated substrate by
APC/C and Ube2S by solving the Cryo-EM structure of substrate-acceptor UB-donor UBUbe2S/Ube2C (full length)-APC/C complex. (Figure 4-13) However, in order to generate a such
complicated protein complex, a few compromises had to be made: the acceptor UB had to be
replaced by a UB variant (UBv) bearing 17 mutations selected from a phage library so that the
acceptor UB can be anchored onto the APC11’s RING with increased affinity (1.6 μM KD); the
substrate peptides had to be fused to N-terminus or C-terminus of acceptor UB to mimic the
ubiquitinated substrate; and most importantly, donor UB, acceptor UB fused with substrate peptide,
and E2 (Ube2S or Ube2C) were crosslinked together with 3-headed sulfhydryl-reactive TMEA.
(Figure 4-14) to mimic the transient UB transfer intermediate. As a result, catalytic core, RINGUBv and E2 portions of the maps displayed local resolution ~6-10 Å with an overall resolution 6
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Å; the donor UB was not visible even at low contour in either complex, suggesting the local
variability or the dynamics of the “closed” E2~UB conjugate in solution. We reasoned a betterdesigned acceptor UB-donor UB-Ube2S could provide a detailed mechanism of K11 chain
elongation by Ube2S by zooming in the catalytic core with closer mimics. (Figure 4-14) To this
end, a collaboration was set up immediately with Dr. Nicolas Brown in University of North
Carolina at Chapel Hill, who published the Cryo-EM structures earlier; we will generate protein
complex shown in Figure 4-13C and he will put it along with APC/C components and determine
the structure by Cryo-EM.

Figure 4-13 Cryo-EM structures of Ube2C/Ube2S and APC/C mediating ubiquitin
initiation and elongation on the substrate.
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Figure 4-14 Comparison of designs to crosslink donor UB-acceptor UB-Ube2S

To generate this newly designed protein complex, a fusion protein comprised of an Nterminal substrate peptide and acceptor UB with unnatural amino acid ThzK incorporated at K11
position was made and well characterized by ESI-POS (Figure 4-15A, B). Then a Flag-tagged
donor UB was made and conjugated to the acceptor UB. (Figure 4-15C, D) The next step is scaling
up the diUB synthesis so that it can conjugated to full length Ube2S; the flexible 66-residue Cterminal extension of Ube2S cannot be crystalized but is very crucial for anchoring itself onto
APC/C complex.203
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Figure 4-15 Preparation of UBK11CysUB fused with APC/C substrate peptide sequence
(A) ThzK incorporation of UBK11ThzK-HSL1
(B) ESI (+) shows the correct molecular weight of UBK11CysK-HSL1, calculated MS 15022.76
(C) Reaction between Donor UB-MesNa and acceptor UBK11CysK-HSL1
(D) The ligation reaction was analyzed by SDS-PAGE coupled with Coomassie staining.
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4.3.2 UBK48CysUB-UBE2G1-Cul4-RBX1-DDB1-SV5 complex
Cullin-Ring E3 ligases236, 237 are a superfamily of RING E3s responsible for as much as
20% of ubiquitin-dependent protein turn-over in cells.238 The basal state of a CRL complex as
being composed of a cullin, a RING finger protein (RBX1 or RBX2) that serves as the site for E2
binding and ubiquitin transfer, and an SR (substrate receptors) module, which specifically recruit
a target protein. CRL relies a specific E2, CDC34 (Ube2R1), to assembly K48-linked UB chains.
The chain specificity of Cdc34 associated with CRL was in part explained by kinetic studies and
site-mutagenesis69, suggesting residues near CDC34 activate site are complementary to the surface
surrounding K48 in acceptor UB. In addition, a recent study of donor UB forming a disulfide with
Cdc34 catalytic cysteine239, revealing key interactions between them. However, detailed
information is still missing for acceptor UB recognition; and how Cdc34 (UBE2G1), along with
its CRLs, mediates the UB chain initiation and elongation on their substrates.
To stress this issue, we are collaborating with Dr. Ning Zheng from University of
Washington who solved lots of structures of CRLs and their substrates.240-244 Based upon the
determined structure of UBE2G1-Cul4-RBX1-DDB1-SV5 (Figure 4-16A, unpublished data from
Zheng lab), we have design the structure of UBK48CysUB-S-S-UBE2G1-SV5 (Figure 4-16B) to
fill in the gap of the whole picture for SV5 ubiquitination and chain elongation. This time, instead
of fusion the substrate SV5 to the N-terminus of acceptor UB. A closer mimic of triazole linkage
introduced by click chemistry was designed to represent the isopeptide bond between SV5 and
acceptor UB: the azide group on C-terminus of acceptor UB for this purpose was generated with
intern-mediated expressed ligation; the propargyl lysine was incorporated into the substrate with
genetic code expansion. (Scheme 4-1)
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Figure 4-17 Structure of Cul4-DDB1-SV1-RBX1-UBE2G1

Figure 4-16 Design of donor UB- acceptor UB-Cdc34 (UBE2G1)-Substrate complex

Scheme 4-1 Synthetic route for UBK48CysUB-UBE2G1-SV5
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Here in this thesis, three pilot reactions are demonstrated, which are three new yet crucial
steps for the donor UB- acceptor UB-UBE2G1-SV5 complex design. First one is incorporating
propargyl lysine into Ubiquitin with decent yield (Figure 4-18A); another one is generating a Cterminal azide utilizing intein-mediated expressed ligation (Figure 4-18B); and the last one is click
reaction between donor UB with an azide and acceptor UB bearing an alkyne, catalyzed by Copper
(I) and Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) (Figure 4-18C).The success of these
experiments suggest the design is reasonable and feasible.
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Figure 4-18 Pilot reactions for donor UB-acceptor UB-UBE2G1-SV5 design
(A) Incorporation of propargyl lysine into UB, characterized by Coomassie staining and ESI (calculated MW
8645.0)
(B) Generation of C-terminal azido UB via intein-mediated expressed ligation, characterized by MALDI-LP
(calculated MW 8589.9)
(C) Click reaction between UB-N3 and UB-alkyne, monitored by SDS-PAGE: Lane 1 Reaction with two
components and Cu(I), THPTA; Lane 2, 3, 4, 5: control reactions omitting THPTA, Cu(I), UB-N3,UB-alkyne
respectively.
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4.4

Conclusion
To summarize, three diUB with different linkage types were made, namely K11, K48 and

K63. These diUB features a thiol as a reactive warhead embedded near the isopeptide site that can
form a three-component complex with Ube2S, HECTHUW1, HECTNEDD4 respectively through
disulfide conjugation upon DTNB pre-activation. A streamline of production of these complexes
had been realized with milligram level yield, hopefully can facilitate more crystallization condition
screening and eventually solve the structures. By doing this, the detailed mechanism and direct
evidence of UB transfer during the chain elongation by linkage-specific E2 or HECT-type E3s are
expected to be revealed.
Nevertheless, by collaborating with crystallographers, donor UB- E2s- acceptor UBcovalently crosslinked with substrate or substrate peptide sequence is rationally designed and
readily made, hoping to fit in the big picture of how linkage-specific E2s, associating with giant
RING E3s such as APC/C or CRLs, initiate the ubiquitin on a certain substrate and further elongate
UB chains in a linkage-specific manner.
Chemical biology expands the toolbox of chemists and biologists and empower them to
address complicated questions that cannot be solved with traditional biochemistry approaches. For
instance, these diUB probes with customized designs and modifications, should provide access for
structural biologists to map dynamic, transient, weak protein-protein interactions in UB transfer,
therefore to uncover detailed mechanism underlying chain specificities of E2 or HECT E3 with
direct evidences and to reconstitute full pictures of E2, E3 mediated ubiquitination on substrates
and linkage-specific chain elongation.
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4.5

Materials and method

4.5.1 Protein expression and purification
Ube2S (UBC domain) was expressed with BL21(DE3) cells as a His-SUMO-Ube2S
fusion and purified with a standard Ni-NTA affinity purification. Then Ulp1 was selected to
cleave the SUMO tag off and tag-free Ube2S was purified with AKTA HisTrap affinity
purification, followed by anion-exchange chromatography.
HUWE1 and NEDD4 HECT domain were expressed with BL21(DE3) cells with an Nterminal His tag. Upon purification with Ni-NTA, 3C protease was selected to cleave the His tag
off and tag-free HUWE1 or NEDD4 was purified with AKTA Histrap affinity purification,
followed by anion-exchange chromatography.
4.5.2 Disulfide formation
Disulfide formation between diUB-Cys and E2 or E3s followed a reported protocol245.
In short, diUB and E2 or E3 with a single cysteine was pretreated with 1 mM TCEP (pH=8.0) and
incubated at 37 °C for half an hour to fully reduce the disulfide. Then diUB and E2 or E3 were
desalted with PD-10 columns in a crosslink buffer (25mM Tris, pH=8.0, 50 mM NaCl). DiUB was
stored on ice until use. E2 or E3 were then added to a freshly made “activation” buffer. (25 mM
Tris, pH=8.0, 50mM NaCl, 2.5 mM 2,2’- Dipyridyldisulfide, 2.5% DMSO) and incubated at 25°C
for half an hour. The resulted yellow solution was then concentrated down to proper volume and
pass through PD-10 desalting column again to remove DTNB in excess. The concentration of both
diUB and E2 or E3 were measured by BSA assay and the disulfide bond was formed by incubated
1 equiv. of diUB along with 2-4 equiv. of E2 or E3. After 1 hour, the reaction mixture was desalted
with PD-10 column and treated with Ni-NTA resin for affinity purification.
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APPENDICES
Appendix A NMR and ESI of unnatural amino acids.
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Figures S1. 1H-NMR and MS(ESI+) of L-ThzK-OH (7a).
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Figures S2. 1H-NMR and MS(ESI+) of D-ThzK-OH (8a).
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Figures S3. 1H-NMR and MS(ESI+) of L-ThzK-OMe (7b).
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Figures S4. 1H-NMR and MS(ESI+) of D-ThzK-OMe (8b).
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Appendix B NMR and ESI for α, αʹ′-Di-bromo-adipyl(bis)amide (DBAA)

